0001630113 2024-04-01 2025-03-31 0001630113 2024-09-30 0001630113 2025-07-15 0001630113 2025-03-31 0001630113 2024-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2025-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-03-31 0001630113 us-gaap:PreferredStockMember 2025-03-31 0001630113 us-gaap:PreferredStockMember 2024-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2025-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2024-03-31 0001630113 2023-04-01 2024-03-31 0001630113 us-gaap:PreferredStockMember 2024-03-31 0001630113 us-gaap:CommonStockMember 2024-03-31 0001630113 BTCY:SharesToBeIssuedMember 2024-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001630113 us-gaap:RetainedEarningsMember 2024-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-03-31 0001630113 BTCY:MezzanineEquityMember 2024-03-31 0001630113 us-gaap:PreferredStockMember 2023-03-31 0001630113 us-gaap:CommonStockMember 2023-03-31 0001630113 BTCY:SharesToBeIssuedMember 2023-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001630113 us-gaap:RetainedEarningsMember 2023-03-31 0001630113 2023-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2023-03-31 0001630113 BTCY:MezzanineEquityMember 2023-03-31 0001630113 us-gaap:PreferredStockMember 2024-04-01 2025-03-31 0001630113 us-gaap:CommonStockMember 2024-04-01 2025-03-31 0001630113 BTCY:SharesToBeIssuedMember 2024-04-01 2025-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2025-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2025-03-31 0001630113 us-gaap:RetainedEarningsMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-04-01 2025-03-31 0001630113 BTCY:MezzanineEquityMember 2024-04-01 2025-03-31 0001630113 us-gaap:PreferredStockMember 2023-04-01 2024-03-31 0001630113 us-gaap:CommonStockMember 2023-04-01 2024-03-31 0001630113 BTCY:SharesToBeIssuedMember 2023-04-01 2024-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2024-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2024-03-31 0001630113 us-gaap:RetainedEarningsMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2023-04-01 2024-03-31 0001630113 BTCY:MezzanineEquityMember 2023-04-01 2024-03-31 0001630113 us-gaap:PreferredStockMember 2025-03-31 0001630113 us-gaap:CommonStockMember 2025-03-31 0001630113 BTCY:SharesToBeIssuedMember 2025-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001630113 us-gaap:RetainedEarningsMember 2025-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2025-03-31 0001630113 BTCY:MezzanineEquityMember 2025-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-04-01 2022-03-31 0001630113 2020-10-01 2021-09-30 0001630113 2021-01-01 2021-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-19 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2025-03-31 0001630113 BTCY:TechnologyFeesMember 2024-04-01 2025-03-31 0001630113 BTCY:TechnologyFeesMember 2023-04-01 2024-03-31 0001630113 BTCY:DeviceSalesMember 2024-04-01 2025-03-31 0001630113 BTCY:DeviceSalesMember 2023-04-01 2024-03-31 0001630113 us-gaap:FairValueInputsLevel1Member 2025-03-31 0001630113 us-gaap:FairValueInputsLevel2Member 2025-03-31 0001630113 us-gaap:FairValueInputsLevel3Member 2025-03-31 0001630113 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001630113 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001630113 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001630113 us-gaap:OfficeEquipmentMember 2025-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001630113 BTCY:TwoSeriesANotesMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember 2021-03-31 0001630113 BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2021-03-31 0001630113 BTCY:SeriesANotesTwoMember 2020-04-01 2021-03-31 0001630113 BTCY:TwoSeriesANotesMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesANotesOneMember 2020-04-01 2021-03-31 0001630113 BTCY:PlacementAgentMember us-gaap:WarrantMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesANotesMember 2022-03-31 0001630113 BTCY:SeriesANoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 0001630113 BTCY:NewConvertibleNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:SeriesANotesMember 2025-03-31 0001630113 BTCY:SeriesANotesMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesANotesMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesANoteMember 2025-03-31 0001630113 BTCY:SeriesANoteMember 2024-03-31 0001630113 BTCY:SeriesANoteMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesANoteMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:AccreditedInvestorsMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2020-04-01 2021-03-31 0001630113 BTCY:SeriesBNotesMember us-gaap:WarrantMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantOneMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember BTCY:WarrantTwoMember 2021-03-31 0001630113 BTCY:SeriesBNotesMember 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2021-04-01 2022-03-31 0001630113 BTCY:SeriesBNotesMember 2022-04-01 2023-03-31 0001630113 2022-04-01 2023-03-31 0001630113 BTCY:SeriesBNotesMember 2023-03-31 0001630113 BTCY:SeriesBNoteMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesBNotesMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesBNoteMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesBNotesMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesBNoteMember 2025-03-31 0001630113 BTCY:SeriesBNoteMember 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesCNotesMember 2025-03-31 0001630113 BTCY:SeriesCNotesMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesCNotesMember us-gaap:WarrantMember 2024-04-01 2025-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesCNotesMember 2024-04-01 2025-03-31 0001630113 BTCY:PlacementAgentMember BTCY:SeriesCNotesMember us-gaap:WarrantMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesCNotesMember BTCY:NoteHoldersMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember BTCY:PlacementAgentsWarrantsMember 2023-10-23 0001630113 BTCY:SeriesCNotesMember 2023-10-23 2023-10-23 0001630113 BTCY:SeriesCNotesMember 2024-03-31 0001630113 BTCY:SeriesCConvertibleNotesMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesCNoteMember 2024-04-01 2025-03-31 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-09-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 2023-10-25 0001630113 BTCY:EighteenMonthAnniversaryMember 2023-10-25 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2024-01-01 2024-01-31 0001630113 BTCY:TwentyFourMonthAnniversaryMember 2024-01-31 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-06-17 2024-06-17 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-06-17 0001630113 BTCY:SixMonthAnniversaryMember 2024-04-01 2025-03-31 0001630113 BTCY:SixMonthAnniversaryMember 2025-03-31 0001630113 BTCY:TwelveMonthAnniversaryMember 2024-04-01 2025-03-31 0001630113 BTCY:TwelveMonthAnniversaryMember 2025-03-31 0001630113 BTCY:EighteenMonthAnniversaryMember 2024-04-01 2025-03-31 0001630113 BTCY:ConvertiblePreferredNotesMember 2024-04-01 2025-03-31 0001630113 BTCY:ConvertiblePreferredNotesMember 2023-04-01 2024-03-31 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 0001630113 BTCY:OtherConvertibleNotesPayableMember 2023-01-23 2023-01-23 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-03-31 0001630113 us-gaap:NotesPayableOtherPayablesMember 2024-04-01 2025-03-31 0001630113 us-gaap:NotesPayableOtherPayablesMember 2023-04-01 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2022-12-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-04-01 2025-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-04-01 2024-03-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-31 0001630113 BTCY:FirstFourWeeksMember BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2022-12-01 2022-12-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-04-01 2025-03-31 0001630113 BTCY:ShortTermCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-04-01 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2022-12-01 2022-12-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2025-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2024-04-01 2025-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorMember 2023-04-01 2024-03-31 0001630113 BTCY:SeriesAConvertibleNoteHoldersMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2022-12-30 2022-12-30 0001630113 BTCY:NewPromissoryNoteMember 2025-03-31 0001630113 BTCY:NewPromissoryNoteMember 2024-04-01 2025-03-31 0001630113 BTCY:NewPromissoryNoteMember 2023-04-01 2024-03-31 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 0001630113 BTCY:FirstFourWeeksMember BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:RemainingThirtySixWeeksMember BTCY:CollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-03-29 2023-03-29 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 2023-07-18 0001630113 BTCY:SeriesANotesMember BTCY:AdditionalCollateralizedBridgeLoanAgreementMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2023-07-18 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2025-03-31 0001630113 BTCY:AdditionalCollateralizedBridgeLoanAgreementMember BTCY:FinanceCompanyMember 2024-04-01 2025-03-31 0001630113 2023-06-01 2023-06-30 0001630113 2023-06-30 0001630113 us-gaap:RevolvingCreditFacilityMember 2025-03-31 0001630113 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 2023-07-13 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-07-13 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember BTCY:OneInvestorMember 2023-08-11 2023-08-11 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2023-08-11 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesOneMember 2023-08-11 2023-08-11 0001630113 BTCY:ShortTermPromissoryNotesTwoMember 2024-03-31 0001630113 BTCY:ShortTermPromissoryNotesTwoMember 2023-04-01 2024-03-31 0001630113 BTCY:TwoShortTermPromissoryNotesMember 2025-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-12-08 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2025-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2024-04-01 2025-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementOneMember BTCY:CollateralizedMerchantFinanceCompanyMember 2023-04-01 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-02-29 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-02-01 2024-02-29 0001630113 BTCY:PromissoryNoteAgreementMember 2025-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2025-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2024-04-01 2025-03-31 0001630113 BTCY:PromissoryNoteAgreementMember BTCY:IndividualInvestorOneMember 2023-04-01 2024-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-02-02 2024-02-02 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-02-02 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2025-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2024-04-01 2025-03-31 0001630113 BTCY:ShortTermBridgeLoanAgreementMember BTCY:CollateralizedMerchantFinanceCompanyOneMember 2023-04-01 2024-03-31 0001630113 2021-12-21 0001630113 2021-12-21 2021-12-21 0001630113 2024-04-01 2024-12-31 0001630113 2024-12-31 0001630113 us-gaap:CashMember 2021-12-21 0001630113 2022-11-01 2022-11-30 0001630113 2024-11-01 2024-11-30 0001630113 2024-11-30 0001630113 BTCY:TermLoanMember 2024-04-01 2025-03-31 0001630113 BTCY:TermLoanMember 2023-04-01 2024-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-01 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2020-04-30 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2021-05-01 2021-05-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2025-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2024-04-01 2025-03-31 0001630113 BTCY:EconomicInjuryDisasterLoanMember 2023-04-01 2024-03-31 0001630113 us-gaap:ConvertibleDebtMember 2024-04-01 2025-03-31 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember 2024-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2025-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2025-03-31 0001630113 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2024-03-31 0001630113 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2024-03-31 0001630113 srt:MinimumMember 2025-03-31 0001630113 srt:MaximumMember 2025-03-31 0001630113 srt:MinimumMember 2024-03-31 0001630113 srt:MaximumMember 2024-03-31 0001630113 us-gaap:ConvertibleDebtMember 2024-03-31 0001630113 us-gaap:ConvertibleDebtMember 2023-03-31 0001630113 us-gaap:ConvertibleDebtMember 2023-04-01 2024-03-31 0001630113 us-gaap:ConvertibleDebtMember 2025-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2025-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2024-04-01 2025-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2024-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember us-gaap:MeasurementInputExpectedTermMember 2023-04-01 2024-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2025-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2025-03-31 0001630113 srt:MinimumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2024-03-31 0001630113 srt:MaximumMember BTCY:ConvertibleNoteAndWarrantDerivativeMember 2024-03-31 0001630113 2025-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2025-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-03-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2025-03-31 0001630113 BTCY:ShareholdersMember BTCY:ExchangeAgreementMember 2024-03-31 0001630113 BTCY:ShareholdersMember 2025-03-31 0001630113 BTCY:ShareholdersMember 2024-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2024-04-01 2025-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2023-09-18 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-12-31 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-10-01 2024-12-31 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 srt:MaximumMember us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 us-gaap:SeriesAPreferredStockMember 2023-09-19 0001630113 BTCY:BeneficiaryMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 BTCY:BeneficiaryMember us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember BTCY:PurchaseAgreementMember 2023-09-18 2023-09-19 0001630113 us-gaap:SeriesBPreferredStockMember 2023-10-01 2023-12-31 0001630113 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001630113 2023-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001630113 BTCY:SharesToBeIssuedMember 2024-01-01 2024-03-31 0001630113 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-04-01 2025-03-31 0001630113 us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-03-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-10-01 2024-10-31 0001630113 BTCY:SeriesBConvertibleRedeemablePreferredStockMember 2024-07-11 2024-07-11 0001630113 us-gaap:SeriesBPreferredStockMember 2024-10-01 2024-12-31 0001630113 us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-12-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2025-03-31 0001630113 2024-10-01 2024-10-31 0001630113 BTCY:ExecutiveMember 2024-10-01 2024-10-31 0001630113 us-gaap:SeriesCPreferredStockMember 2024-04-01 2025-03-31 0001630113 BTCY:ConsultantMember 2024-04-01 2025-03-31 0001630113 srt:DirectorMember 2024-04-01 2025-03-31 0001630113 BTCY:SeriesCConvertibleNoteMember 2024-10-01 2025-03-31 0001630113 BTCY:SeriesCNotesMember us-gaap:CommonStockMember 2024-04-01 2025-03-31 0001630113 BTCY:NoteHolderWarrantMember 2023-04-01 2024-03-31 0001630113 BTCY:PlacementAgentWarrantsMember 2023-04-01 2024-03-31 0001630113 BTCY:NoteHolderMember 2024-03-31 0001630113 BTCY:PlacementAgentWarrantsMember 2024-03-31 0001630113 us-gaap:WarrantMember 2024-03-31 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-04-01 2022-06-30 0001630113 2022-06-30 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0001630113 2022-09-30 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-10-01 2022-12-31 0001630113 BTCY:ExecutiveMember us-gaap:WarrantMember 2022-12-31 0001630113 us-gaap:WarrantMember 2022-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2024-04-01 2025-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2023-04-01 2024-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2025-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2024-03-31 0001630113 BTCY:TwoThousandAndTwentyThreeEquityIncentivePlanMember 2023-03-31 0001630113 BTCY:BrokerWarrantsMember 2023-03-31 0001630113 BTCY:ConsultantWarrantsMember 2023-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2023-03-31 0001630113 BTCY:BrokerWarrantsMember 2023-04-01 2024-03-31 0001630113 BTCY:ConsultantWarrantsMember 2023-04-01 2024-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2023-04-01 2024-03-31 0001630113 BTCY:BrokerWarrantsMember 2024-03-31 0001630113 BTCY:ConsultantWarrantsMember 2024-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-03-31 0001630113 BTCY:BrokerWarrantsMember 2024-04-01 2025-03-31 0001630113 BTCY:ConsultantWarrantsMember 2024-04-01 2025-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2024-04-01 2025-03-31 0001630113 BTCY:BrokerWarrantsMember 2025-03-31 0001630113 BTCY:ConsultantWarrantsMember 2025-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2025-03-31 0001630113 srt:MinimumMember BTCY:BrokerWarrantsMember 2025-03-31 0001630113 srt:MaximumMember BTCY:BrokerWarrantsMember 2025-03-31 0001630113 srt:MinimumMember BTCY:ConsultantWarrantsMember 2025-03-31 0001630113 srt:MaximumMember BTCY:ConsultantWarrantsMember 2025-03-31 0001630113 us-gaap:StockOptionMember 2024-03-31 0001630113 us-gaap:StockOptionMember 2024-04-01 2025-03-31 0001630113 us-gaap:StockOptionMember 2025-03-31 0001630113 us-gaap:StockOptionMember 2023-03-31 0001630113 us-gaap:StockOptionMember 2023-04-01 2024-03-31 0001630113 srt:MinimumMember 2024-04-01 2025-03-31 0001630113 srt:MaximumMember 2024-04-01 2025-03-31 0001630113 BTCY:NewLeaseAgreementMember 2021-12-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2025-03-31 0001630113 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2024-03-31 0001630113 2022-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001630113 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001630113 us-gaap:OfficeEquipmentMember 2023-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001630113 us-gaap:OfficeEquipmentMember 2023-04-01 2024-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2023-04-01 2024-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001630113 us-gaap:OfficeEquipmentMember 2024-04-01 2025-03-31 0001630113 us-gaap:LeaseholdImprovementsMember 2024-04-01 2025-03-31 0001630113 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2025-04-01 2025-07-14 0001630113 us-gaap:CommonStockMember 2025-03-30 2025-03-30 0001630113 us-gaap:SeriesBPreferredStockMember 2025-04-01 2025-07-14 0001630113 us-gaap:SubsequentEventMember 2025-04-01 2025-07-14 0001630113 us-gaap:SubsequentEventMember 2025-07-14 iso4217:USD shares iso4217:USD shares pure false FY 0001630113

10-K true 2025-03-31 --03-31 2025 false 001-40761 BIOTRICITY INC. NV 30-0983531 203 Redwood Shores Parkway Suite 600 Redwood City CA 94065 800 590-4155 Common Stock, Par Value $0.001 No No Yes Yes Non-accelerated Filer true false false false false 2787999 26567769 None ITEM 1C. CYBERSECURITY <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240401__20250331_zfoHXgdkaEY2">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240401__20250331_zvN7ZbXPazq4">integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">34</td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"> </div> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240401__20250331_zz7ufy0ksVOi">We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks. Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with Vice President of Technology, who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process. We engage consultants, or other <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240401__20250331_zN0tenOLoCh4">third parties in connection with our risk assessment processes. These service providers assist us to design and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards. We require each third-party service provider to certify that it has the ability to implement and maintain appropriate security measures, consistent with all applicable laws, to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of its security measures that may affect our company. We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing. We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240401__20250331_zvN7ZbXPazq4">integrated these processes into our overall risk management systems and processes. true We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks. true Governance <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240401__20250331_zebf3x8zn8Qa">Our board of directors addresses the Company’s cybersecurity risk management as part of its general oversight function. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240401__20250331_zus8ToDqkol7">The board of directors’ audit committee is responsible for overseeing Company’s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats. Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the information technology team at the direction of our Vice President of Technology. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240401__20250331_zNTGpTlyIiI9">Our executive team including our Chief Executive Officer, and Chief Financial Officer are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company’s overall risk management strategy, and communicating key priorities to relevant personnel. This executive team is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Chief Executive Officer, and Chief Financial Officer. In addition, the Company’s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents including significant breaches to the Company’s networks or systems. The audit committee receives regular reports from the information technology team concerning the Company’s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to the Vice President of Technology, to receive various reports, summaries or presentations related to cybersecurity threats, risk and mitigation. Our board of directors addresses the Company’s cybersecurity risk management as part of its general oversight function. true Our executive team including our Chief Executive Officer, and Chief Financial Officer are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company’s overall risk management strategy, and communicating key priorities to relevant personnel. false false false false 5828 We have audited the accompanying consolidated balance sheets of Biotricity Inc. and its subsidiary (the Company) as of March 31, 2025 and 2024 and the related consolidated statements of operations and comprehensive loss, mezzanine equity and stockholders’ deficiency, and cash flows for each of the years in the two-year period ended March 31, 2025 and related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2025 and 2024 and the results of its operations and its cash flows for each of the years in the two-year period ended March 31, 2025, in conformity with accounting principles generally accepted in the United States of America. SRCO Professional Corporation Richmond Hill, Ontario, Canada

365145

786060

1658772

1468655

1555385

1879402

1059990

336456

4639292

4470573

109297

85000

70713

149907

9599

15552

812053

1221593

5640954

5942625

7661924

9613118

9618738

9236471

2400000

424200

991866

531286

457371

20636148

22698826

870800

12271559

9985033

1478717

1435668

397830

929115

35655054

35919442

0.001

600

385

265

2000290

1488920

0.001

9979400

0.001

20000

200

6304

0.001

125000000

26081295

9353768

160672

26243

9515

581599 324276 284244 269065

106971115

95723083

145792

32378

-139441785

-127499785

-32014390

-31465737

5640954

5942625

13790294

12063345

3225803

3707064

10564491

8356281

10857797

14612724

2155660

2571826

13013457

17184550

-2448966

-8828269

-78569

-102607

3262038

3018803

-137934

18539

-1939816

-2172920

-553856

9777

-8421179

-14094283

-8421179

-14094283

466141

834677

-3054680

-11942000

-14928960

113414

185175

-11828586

-14743785

-0.555

-1.660

21524884

8991766

265

1488920

6305

9514440

9515

344276

269065

95723083

32378

-127499785

-31465737

220

1082999

97811 98 125129 125227 -100

-571630

4365022

4365

-288786

1240257

1015836

-6104 -6 8952170 8952 4925756 4934702 1595445 1595 577644 259245 2107338 2431178

716666

717

-15280

335446

320883

1000413 1000 989408 990409

1461698

113414

-8421179

466141 466141 -3054680 -3054680

385

2000290

201

26241967

26243

581599

284244

106971115

145792

-139441785

-32014390

6305

8752510

8753

3955

24999

92844478

-152797

-112570825

-19845385

6305

8752510

8753

3955

24999

92844478

-152797

-112570825

-19845385

20846

21 -21 36897 37 119248 119285

330

1860554

1137716 1137716 141070 141070 -65 -371634 -371634

612062

612

320321

228786

353907

583305

92125

20000

15280

100755

116127

1025930

185175

-14094283

834677 834677

265

1488920

6305

9514440

9515

344276

269065

95723083

32378

-127499785

-31465737

265

1488920

6305

9514440

9515

344276

269065

95723083

32378

-127499785

-31465737

-8421179

-14094283

1461698

1025930

320883

116127

-1939816

-2172920

-553856

9777

137934 -18539 249093 59161

5953

409540

365899

110923

298248

-324017

-457604

747831

-252143

1496966

3271198

-2380177

-6693912

125227

119285

1732532

2825000

1835000

2962386

-1733516

853030

29984 18016

1929259

6741685

30003

167827

-450918

47773

786060

570460

365145

786060

3611939

2022221

1. NATURE OF OPERATIONS Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company” or “Biotricity”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016. Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States dollars (“USD”). The consolidated financial statements of the Company have been prepared on a historical cost basis except Cash and derivative liabilities which are carried at fair value. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Significant intercompany accounts and transactions have been eliminated. Reclassifications Certain amounts presented in the prior year period have been reclassified to conform to current period consolidated financial statement presentation. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Going Concern, Liquidity and Basis of Presentation The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory clearance for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as of March 31, 2025, had an accumulated deficit of $139,441,785 (2024: $127,499,785) and a working capital deficiency of $15,996,856 (2024: $ 18,228,253). Those conditions raise substantial doubt about its ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements. The consolidated financial statements do not include adjustments that might result from the outcome of this uncertainty. Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity and debt capitalization of the Company. During fiscal year ended March 31, 2022, the Company raised $499,900 through government EIDL loan. During the fiscal quarter ended September 30, 2021, the Company also raised total net proceeds of $14,545,805 through the underwritten public offering that was concurrent with its listing onto the Nasdaq Capital Markets. During the fiscal quarter ended December 31, 2021, the Company raised additional net proceeds of $11,756,563 through a term loan transaction (Note 6) and made repayment of the previously issued promissory notes and short-term loans. In connection with this loan, the Company and Lender entered into a Guarantee and Collateral Agreement, as well as an Intellectual Property Security Agreement, wherein the Company agreed to secure the Credit Agreement with all of the Company’s assets, as well as secured by the Company’s right title and interest in the Company’s Intellectual Property. During the fiscal year ended March 31, 2024, the Company raised short-term loans and promissory notes, net of repayments of $853,030 from various lenders, and also raised convertible notes, net of redemptions of $2,962,386 from various lenders. The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying a 3% placement fee and other issuance expenses. Additionally, on September 19, 2023, the Company entered into a security purchase agreement with an institutional investor for the issuance and sale of 220 shares of the Company’s newly designated Series B Convertible Preferred Stock, $0.001 par value (the “Series B Preferred Stock”), at a purchase price of $<span id="xdx_902_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zphqiRQsb4P1" title="Preferred stock convertible purchase price">9,091 per share of Series B Preferred Stock (Note 9), or gross proceeds of $2,000,000. Net proceeds after issuance costs amounted to $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20230919__20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKS1FqaZYgVj" title="Net proceeds issuance costs">1,900,000 for the Series B Preferred Stock. During the year ended March 31, 2025, the Company issued an additional <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQ1qkT4CaL6j" title="Stock issued during period">220 Series B preferred shares for net proceeds of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zdyPutSbyvq8" title="Stock issued during period, value">1,732,532. Shares of Series B Preferred Stock and shares of common stock of the Company that are issuable upon conversion of, or as dividends on, the Series B Preferred Stock were offered and were issued pursuant to the Prospectus Supplement, filed September 19, 2023, to the Prospectus included in the Company’s Registration Statement on Form S-3 (Registration No. 333-255544) filed with the Securities and Exchange Commission on April 27, 2021, and declared effective May 4, 2021. As we proceed with the commercialization of the Bioflux, Biocore, and Biocare product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures. Based on the above facts and assumptions, we believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines.

-139441785

-127499785

-15996856 -18228253

499900

14545805

11756563

853030

2962386

36897 123347

119285

0.03

220

0.001

9091

2000000

1900000

220

1732532

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. <p id="xdx_89C_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zPVfXo4Ytvrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recognized the following forms of revenue for the fiscal years ended March 31, 2025 and 2024: SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240401__20250331_zEECi3ykXga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230401__20240331_z8i2zJR9vx3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesMember_zGk5FVsZCT81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Technology fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">12,591,036</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">11,249,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_zER3zIWijlk6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Device sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,199,258</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">814,232</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zPo3vKSH6Vk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Revenue recognized</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,790,294</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,063,345</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Inventories Inventory is stated at the lower of cost and net realizable value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250331_zlZx23iH9Dx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240331_zMiCP7eVGD71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzF7M_zEbwNAukfip8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,225,665</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,128,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maINzF7M_z2InlQZ7dZr6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">329,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,702</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_mtINzF7M_zymRO0tG4QHa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Inventories</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,555,385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,879,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Significant accounting estimates and assumptions The preparation of the consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of stock options</td></tr> </table> The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of warrants</td></tr> </table> In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of derivative liabilities</td></tr> </table> In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional currency</td></tr> </table> Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Useful life of property and equipment</td></tr> </table> The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provisions</td></tr> </table> Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingencies</td></tr> </table> Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory obsolescence</td></tr> </table> Inventories are stated at the lower of cost and net realizable value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income and other taxes</td></tr> </table> The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incremental borrowing rate for lease</td></tr> </table> The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements. Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method was not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented. Cash Cash includes cash on hand and balances with banks. As of March 31, 2025, and 2024, cash balance of US$ 259,478 and US$ 752,399 were at financial institutions in the United States that were not covered by the United States Deposit Protection Regulation. Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiary from their functional currency into the Company’s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the consolidated balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations. Accounts Receivable Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible. Customer Concentration During the year ended March 31, 2025, one customer comprised 29% of total account receivables, there was no such concentration risk during the previous year ended March 31,2024. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally guaranteed loans, term loans and accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. <p id="xdx_89A_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zKH2BONv9Lm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Cash_iI_c20250331_zouG5kjs2NUd" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">365,145</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWF4dLpTaON2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">365,145</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziepqmUGQ74f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzonne23H5xa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250331_z486oQYpyG09" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">365,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM6U7SCkuzyf" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">365,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfmptXbLL9pk" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoYVB0pPXiR3" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331_zl0wgiBrf4Hg" style="text-align: right" title="Derivative liabilities, short-term">424,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLMmem9Vr0Zk" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zor47V4KjhDc" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0KSpXqbx5Yf" style="text-align: right" title="Derivative liabilities, short-term">242,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331_ztxPO1b3Ffa9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,478,717</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znz6Bsc00XKk" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaVtJnRQzPr4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2h5Xrex0ch4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,478,717</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331_zmBTaMv0tTL1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">1,902,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZE8xyU4Sduf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z56Fb7LA9YFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLfdw1qKX5W1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">1,902,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of March 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Cash_iI_c20240331_zkae0XlyKUO5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z684mu0gTrwh" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zewtdt8wnwCf" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zefKooDaID8f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20240331_zoei68lmNboi" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHUKQJzYPdff" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgl1mzjRl8a4" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgCemJC5CJrg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331_zMjmAtD6kMfe" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcaaE8AZVKsj" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwBmUqjh2VT9" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zs3uFv2XGbZ8" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331_zC86aFBRLJw1" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zstDNHdtiaW4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbkMPiLs87e2" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeF1BUFjkLN5" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331_z62Pb9BStsDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcoYwYo9ulba" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPMjXifAwdx4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdhK0JjjBen2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) There were no transfers between fair value hierarchy levels during the years ended March 31, 2025 and 2024. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zlUA9AEExVtf" title="Property and equipment, useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwVz0SJJW4Yg" title="Property and equipment, useful life">5 years</td></tr> </table> Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at March 31, 2025 and 2024, the Company believes there was no impairment of its long-lived assets. Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 12 for further discussion. Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product. Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relation and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses. Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services. Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Series B Convertible Preferred Stock The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815. Preferred Share Redemption and Conversions The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For Series A preferred stock redemptions, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. For Series B preferred stock conversions, no gain or loss is recognized upon Series B preferred stock conversion except for the fair value adjustment for the conversion and redemption feature derivative liabilities on the conversion date. Segment Information Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (“CEO”) as the chief operating decision maker (“CODM”). The Company operates in one operating segment. The Company’s CODM allocates resources and assesses performance at the consolidated level. The Company’s property and equipment and operating right of use lease asset are in the United States as of March 31, 2025 and 2024. The CODM uses net loss for purposes of making operating decisions, allocating resources, and evaluating financial performance. Significant expenses include non-cash stock-based compensation, depreciation and amortization, and write-off of property and equipment, which are reflected in the Consolidated Statements of Cash Flows for the years ended March 31, 2025 and 2024. The long-lived assets outside of U.S. are not material as of March 31, 2025. The measure of segment assets is reported on the balance sheet as total consolidated assets. Refer to the Consolidated Balance Sheets as of March 31, 2025 and 2024 for total consolidated assets. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Company’s consolidated financial statements according to the effective date and the adoption has no significant impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows. On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting the standard. In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to improve the disclosures regarding a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The Company is required to adopt the guidance in the fourth quarter of fiscal 2025, though early adoption is permitted. The Company adopted the new standard during the current year and conclude that there is no material impact. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures (“ASU 2023-09”) to provide disaggregated income tax disclosures on rate reconciliation and income taxes paid. The Company is required to adopt the guidance in the fourth quarter of fiscal 2026, though early adoption is permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements. The Company continue to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

Revenue Recognition The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Both the Bioflux mobile cardiac telemetry device, and the Biocore device are wearable devices. The cardiac data that the devices monitor and collect is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned are comprised of device sales revenues and technology fee revenues (technology as a service). The devices, together with their licensed software, are available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized. The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business. <p id="xdx_89C_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zPVfXo4Ytvrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recognized the following forms of revenue for the fiscal years ended March 31, 2025 and 2024: SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240401__20250331_zEECi3ykXga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230401__20240331_z8i2zJR9vx3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesMember_zGk5FVsZCT81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Technology fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">12,591,036</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">11,249,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_zER3zIWijlk6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Device sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,199,258</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">814,232</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zPo3vKSH6Vk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Revenue recognized</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,790,294</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,063,345</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

<p id="xdx_89C_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zPVfXo4Ytvrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recognized the following forms of revenue for the fiscal years ended March 31, 2025 and 2024: SCHEDULE OF REVENUE RECOGNITION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240401__20250331_zEECi3ykXga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230401__20240331_z8i2zJR9vx3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesMember_zGk5FVsZCT81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Technology fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">12,591,036</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">11,249,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_zER3zIWijlk6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Device sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,199,258</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">814,232</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zPo3vKSH6Vk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Revenue recognized</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,790,294</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,063,345</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

12591036

11249113

1199258

814232

13790294

12063345

Inventories Inventory is stated at the lower of cost and net realizable value, cost being determined on a weighted average cost basis. Market value of our finished goods inventory and raw material inventory is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250331_zlZx23iH9Dx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240331_zMiCP7eVGD71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzF7M_zEbwNAukfip8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,225,665</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,128,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maINzF7M_z2InlQZ7dZr6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">329,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,702</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_mtINzF7M_zymRO0tG4QHa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Inventories</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,555,385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,879,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250331_zlZx23iH9Dx3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240331_zMiCP7eVGD71" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzF7M_zEbwNAukfip8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw material</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,225,665</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,128,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maINzF7M_z2InlQZ7dZr6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">329,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">750,702</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_mtINzF7M_zymRO0tG4QHa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Inventories</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,555,385</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,879,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1225665

1128700

329720

750702

1555385

1879402

Significant accounting estimates and assumptions The preparation of the consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of stock options</td></tr> </table> The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of warrants</td></tr> </table> In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value of derivative liabilities</td></tr> </table> In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional currency</td></tr> </table> Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Useful life of property and equipment</td></tr> </table> The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provisions</td></tr> </table> Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingencies</td></tr> </table> Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory obsolescence</td></tr> </table> Inventories are stated at the lower of cost and net realizable value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income and other taxes</td></tr> </table> The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incremental borrowing rate for lease</td></tr> </table> The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements.

Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s warrants, options, convertible promissory notes, convertible preferred stock, shares to be issued and restricted stock awards while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options, shares to be issued and restricted stock awards. Diluted earnings with respect to the convertible promissory notes and convertible preferred stock utilizing the if-converted method was not applicable during the periods presented as no conditions required for conversion had occurred. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.

Cash Cash includes cash on hand and balances with banks. As of March 31, 2025, and 2024, cash balance of US$ 259,478 and US$ 752,399 were at financial institutions in the United States that were not covered by the United States Deposit Protection Regulation.

259478

752399

Foreign Currency Translation The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiary from their functional currency into the Company’s reporting currency of United States dollars, consolidated balance sheet accounts are translated using the closing exchange rate in effect at the consolidated balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in accumulated other comprehensive loss in stockholders’ deficiency. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

Accounts Receivable Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short term loans, federally guaranteed loans, term loans and accounts payable and accrued liabilities. The Company’s derivative liabilities are carried at fair values and are classified as Level 3 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. <p id="xdx_89A_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zKH2BONv9Lm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Cash_iI_c20250331_zouG5kjs2NUd" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">365,145</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWF4dLpTaON2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">365,145</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziepqmUGQ74f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzonne23H5xa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250331_z486oQYpyG09" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">365,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM6U7SCkuzyf" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">365,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfmptXbLL9pk" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoYVB0pPXiR3" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331_zl0wgiBrf4Hg" style="text-align: right" title="Derivative liabilities, short-term">424,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLMmem9Vr0Zk" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zor47V4KjhDc" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0KSpXqbx5Yf" style="text-align: right" title="Derivative liabilities, short-term">242,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331_ztxPO1b3Ffa9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,478,717</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znz6Bsc00XKk" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaVtJnRQzPr4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2h5Xrex0ch4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,478,717</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331_zmBTaMv0tTL1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">1,902,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZE8xyU4Sduf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z56Fb7LA9YFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLfdw1qKX5W1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">1,902,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of March 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Cash_iI_c20240331_zkae0XlyKUO5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z684mu0gTrwh" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zewtdt8wnwCf" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zefKooDaID8f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20240331_zoei68lmNboi" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHUKQJzYPdff" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgl1mzjRl8a4" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgCemJC5CJrg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331_zMjmAtD6kMfe" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcaaE8AZVKsj" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwBmUqjh2VT9" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zs3uFv2XGbZ8" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331_zC86aFBRLJw1" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zstDNHdtiaW4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbkMPiLs87e2" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeF1BUFjkLN5" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331_z62Pb9BStsDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcoYwYo9ulba" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPMjXifAwdx4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdhK0JjjBen2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) There were no transfers between fair value hierarchy levels during the years ended March 31, 2025 and 2024.

<p id="xdx_89A_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zKH2BONv9Lm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of financial instruments measured on a recurring basis is as follows: SCHEDULE OF FAIR VALUE OF FINANCIAL INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Cash_iI_c20250331_zouG5kjs2NUd" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">365,145</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWF4dLpTaON2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">365,145</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziepqmUGQ74f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Cash_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzonne23H5xa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20250331_z486oQYpyG09" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">365,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zM6U7SCkuzyf" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">365,145</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfmptXbLL9pk" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoYVB0pPXiR3" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331_zl0wgiBrf4Hg" style="text-align: right" title="Derivative liabilities, short-term">424,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLMmem9Vr0Zk" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zor47V4KjhDc" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0KSpXqbx5Yf" style="text-align: right" title="Derivative liabilities, short-term">242,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331_ztxPO1b3Ffa9" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,478,717</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znz6Bsc00XKk" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaVtJnRQzPr4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2h5Xrex0ch4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,478,717</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331_zmBTaMv0tTL1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">1,902,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zZE8xyU4Sduf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z56Fb7LA9YFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLfdw1qKX5W1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">1,902,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of March 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-bottom: 1pt">Cash</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Cash_iI_c20240331_zkae0XlyKUO5" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z684mu0gTrwh" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">786,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zewtdt8wnwCf" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Cash_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zefKooDaID8f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Cash">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20240331_zoei68lmNboi" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHUKQJzYPdff" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">786,060</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgl1mzjRl8a4" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgCemJC5CJrg" style="border-bottom: Black 1pt solid; text-align: right" title="Total assets at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Derivative liabilities, short-term</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331_zMjmAtD6kMfe" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcaaE8AZVKsj" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwBmUqjh2VT9" style="text-align: right" title="Derivative liabilities, short-term">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zs3uFv2XGbZ8" style="text-align: right" title="Derivative liabilities, short-term">991,866</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities, long-term</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331_zC86aFBRLJw1" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zstDNHdtiaW4" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbkMPiLs87e2" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeF1BUFjkLN5" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, long-term">1,435,668</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331_z62Pb9BStsDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcoYwYo9ulba" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPMjXifAwdx4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdhK0JjjBen2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities at fair value">2,427,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

365145

424200

242200

1478717

1902917

786060

991866

1435668

2427534

Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. Depreciation of property and equipment is provided using the straight-line method for all assets with estimated lives as follow: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zlUA9AEExVtf" title="Property and equipment, useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwVz0SJJW4Yg" title="Property and equipment, useful life">5 years</td></tr> </table>

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify">Office equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zlUA9AEExVtf" title="Property and equipment, useful life">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Leasehold improvement</td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwVz0SJJW4Yg" title="Property and equipment, useful life">5 years</td></tr> </table>

P5Y

Impairment for Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at March 31, 2025 and 2024, the Company believes there was no impairment of its long-lived assets.

Leases The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items Operating right of use assets, Operating lease obligations, current, and Operating lease obligations, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. As the Company’s lease does not provide implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 12 for further discussion.

Income Taxes The Company accounts for income taxes in accordance with ASC 740. The Company provides for Federal, State and Provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for consolidated financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.

Research and Development Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.

Selling, General and Administrative Selling, general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include sales and marketing costs, investor relation and legal costs relating to corporate matters, professional fees for consultants assisting with business development and financial matters, and office and administrative expenses.

Stock Based Compensation The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the consolidated statements of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.

Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Series B Convertible Preferred Stock The Series B convertible preferred stock (“Series B Preferred Stock”) was accounted for as mezzanine equity and the embedded conversion and redemption features was accounted for as derivative liabilities with change in fair value at each reporting period end charged to the consolidated statement of operation and comprehensive loss in accordance with ASC 480 and ASC 815. Preferred Share Redemption and Conversions The Company accounted for preferred stock redemptions and conversions in accordance to ASU-260-10-S99. For Series A preferred stock redemptions, the difference between the fair value of consideration transferred to the holders of the preferred stock and the carrying amount of the preferred stock is accounted as deemed dividend distribution and subtracted from net loss. For Series B preferred stock conversions, no gain or loss is recognized upon Series B preferred stock conversion except for the fair value adjustment for the conversion and redemption feature derivative liabilities on the conversion date.

Segment Information Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company has identified its Chief Executive Officer (“CEO”) as the chief operating decision maker (“CODM”). The Company operates in one operating segment. The Company’s CODM allocates resources and assesses performance at the consolidated level. The Company’s property and equipment and operating right of use lease asset are in the United States as of March 31, 2025 and 2024. The CODM uses net loss for purposes of making operating decisions, allocating resources, and evaluating financial performance. Significant expenses include non-cash stock-based compensation, depreciation and amortization, and write-off of property and equipment, which are reflected in the Consolidated Statements of Cash Flows for the years ended March 31, 2025 and 2024. The long-lived assets outside of U.S. are not material as of March 31, 2025. The measure of segment assets is reported on the balance sheet as total consolidated assets. Refer to the Consolidated Balance Sheets as of March 31, 2025 and 2024 for total consolidated assets.

Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective for fiscal years beginning after December 15, 2022. The Company has adopted Topic 326 on the Company’s consolidated financial statements according to the effective date and the adoption has no significant impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. There is no significant impact from adopting ASU 2019-12 on the Company’s financial condition, results of operations, and cash flows. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company adopted this guidance for the fiscal year beginning April 1, 2022. There is no significant impact from adopting ASU 2021-04 on the Company’s financial condition, results of operations, and cash flows. On March 28, 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements. ASU 2023-01 is designed to clarify the accounting for leasehold improvements associated with common control leases, thereby reducing diversity in practice. The new standard is effective for the Company for its fiscal year beginning January 1, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting the standard. In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to improve the disclosures regarding a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The Company is required to adopt the guidance in the fourth quarter of fiscal 2025, though early adoption is permitted. The Company adopted the new standard during the current year and conclude that there is no material impact. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures (“ASU 2023-09”) to provide disaggregated income tax disclosures on rate reconciliation and income taxes paid. The Company is required to adopt the guidance in the fourth quarter of fiscal 2026, though early adoption is permitted. The Company is currently evaluating the impact of this amendment on its consolidated financial statements. The Company continue to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zv5o9Hl7OeSe" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250331_zNIEZL13mN7g" style="border-bottom: Black 1pt solid; text-align: center">As at March 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240331_zgvFJoEruLxd" style="border-bottom: Black 1pt solid; text-align: center">As at March 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableOtherCurrent_iI_maAPAALzJVu_zzXW6iW5wdTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Trade and other payables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,602,309</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">5,221,992</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzJVu_zkBiobTlRRVi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,034,293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,369,576</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredRevenue_iI_maAPAALzJVu_z9PFE4SQ4uyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,550</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzJVu_zDFOccehcHv2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,661,924</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,613,118</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Trade and other payables and accrued liabilities as at March 31, 2025 and 2024 included $373,744 and $837,945, respectively, due to a shareholder, who is a director and executive of the Company.

<p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zv5o9Hl7OeSe" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250331_zNIEZL13mN7g" style="border-bottom: Black 1pt solid; text-align: center">As at March 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240331_zgvFJoEruLxd" style="border-bottom: Black 1pt solid; text-align: center">As at March 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableOtherCurrent_iI_maAPAALzJVu_zzXW6iW5wdTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Trade and other payables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,602,309</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">5,221,992</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iI_maAPAALzJVu_zkBiobTlRRVi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,034,293</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,369,576</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredRevenue_iI_maAPAALzJVu_z9PFE4SQ4uyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21,550</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_mtAPAALzJVu_zDFOccehcHv2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,661,924</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,613,118</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

4602309

5221992

3034293

4369576

25322

21550

7661924

9613118

373744

837945

5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS Series A Convertible Promissory Notes: During the year ended March 31, 2021, the Company issued $11,275,500 (face value) in two series of convertible promissory notes (the “Series A Notes”) sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 12% per annum. For the first series of Series A Notes, commencing six months following the Issuance Date, and at any time thereafter (provided the Holder has not received notice of the Company’s intent to prepay the note), at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Outstanding Balance”) could be converted into that number of shares of Common Stock equal to: <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20200401__20210331__us-gaap--DebtInstrumentAxis__custom--SeriesANotesOneMember_zKHvLkl8yEO2" title="Description of conversion terms for debt instrument">(i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price). For the first series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest. For the second series of Series A Notes, the notes could be converted into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $24.00 per share or <span id="xdx_908_ecustom--VolumeWeightedAveragePriceOfCommonStockPercent_iI_dp_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesANotesTwoMember_ziRE1Y6PsPWh" title="Volume weighted average price of common stock, percent">75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date. For the second series of Series A Notes, the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) <span id="xdx_904_ecustom--PlacementAgentFeesDescription_c20200401__20210331__us-gaap--DebtInstrumentAxis__custom--TwoSeriesANotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHGipB6Cjxi2" title="Placement agent fees description">The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. <span id="xdx_90D_ecustom--PlacementAgentFeesDescription_c20200401__20210331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--DebtInstrumentAxis__custom--SeriesANotesOneMember_zr5E1tyLb4kg" title="Placement agent fees description">The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes. <span id="xdx_90D_ecustom--PlacementAgentFeesDescription_c20200401__20210331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRc4iYTh7nLl" title="Placement agent fees description">The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $6.36 per share. Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features contained in those Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features. For the Series A Notes, The Company recognized debt issuance costs in the amount of $2,301,854 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Notes. The Company also recognized initial debt discount in the amount of $8,088,003 and accreted the interest over the remaining lives of those Notes. The debt issuance costs were fully amortized by March 31, 2022. On December 30, 2022, the Company exchanged $500,000 of Series A Notes along with its outstanding interest accrual of $121,500 into a new convertible note with the same note holder. The new convertible note has principal of $621,500, stated interest rate of 12% per annum, as well as option to convert outstanding principal and accrued interest at the conversion price, calculated at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20221230__20221230__us-gaap--DebtInstrumentAxis__custom--NewConvertibleNoteMember_zUODKeGF8Pl7" title="Debt instrument interest rate">75% multiplied by the average of the three lowest closing prices during the previous ten trading days prior to the receipt of the conversion notice. The new convertible note matured on December 30, 2023. During the year ended March 31 2025,, all of the Series A notes had been converted into common shares, with the exception of notes held by two investors, with a remaining face value in the amount of $821,000. During the year ended March 31, 2025, the Company recognized discount amortization of $nil (2024: $49,393) as accretion and amortization expense. As of March 31, 2024, the discount on Series A convertible notes was fully amortized. As of March 31, 2025, and March 31, 2024, the Company recorded $272,342 and $173,762, respectively, of interest accruals for the Series A Notes. During the years ended March 31, 2025, and March 31, 2024, the Company recognized interest expense in the amount of $98,580 and $98,850, respectively. Series B Convertible Notes During the year ended March 31, 2021, the Company also issued $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorsMember_zjW4SrrIhYZ1" title="Face amount">1,312,500 (face value) of convertible promissory notes (“Series B Notes”) to various accredited investors. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Commencing six months following the issuance date, and at any time thereafter, subject to the Company’s Conversion Buyout clause, at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the “outstanding balance”) could be converted into that number of shares of Common Stock equal to: (i) the outstanding balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice. The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX0HheKfbTz7" title="Warrants and rights outstanding term">3-year term from date of issuance and an exercise price that is $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zcyY1Qprvsy8" title="Exercise price">6.36 per share for <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zwP0iJ661Zof" title="Warrants issued">100,000 warrant shares and $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zo2yADUVf5xf" title="Exercise Price">9.0 per share for <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember_zJ4gTLHO6qme" title="Warrants issued">35,417 warrant shares. Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features. The Company recognized debt issuance costs in the amount of $10,000 and treated these as a deduction from the convertible note liabilities directly, as a contra-liability, and amortized the debt issuance cost over the term of the Series B Notes. The Company recognized initial debt discount in the amount of $1,312,500 and accreted the interest over the remaining lives of those notes. The debt issuance costs were fully amortized by March 31, 2022. During the year ended March 31, 2022, $472,500 (face value) of Series B Notes were converted into <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210401__20220331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember_zrO7rI9PrKra" title="Converted instrument shares issued">34,586 common shares. As at March 31, 2022, $840,000 of Series B Notes remained unconverted and outstanding, which was equal to the face value of the relevant convertible notes. During the year ended March 31, 2023, $555,600 (face value) of Series B Notes were converted into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20220401__20230331__us-gaap--DebtInstrumentAxis__custom--SeriesBNotesMember_zh39c7owymu8" title="Converted instrument shares issued">126,833 common shares (Note 9 d). During the year ended March 31, 2023, $126,680 (face value) of Series B Notes were redeemed by cash payment of $145,682. The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note, was $24,408, and was recognized as a gain upon convertible note repayment. During the year ended March 31, 2025, the Company redeemed $22,009 of Series B Notes, through a cash payment of $25,342. A gain on redemption $8,320 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($8,320 for the year ended March 31, 2025). During the year ended March 31, 2024, the Company redeemed $135,710 of Series B Notes, through a cash payment of $162,851. A gain on redemption $18,540 was recognized as a result of this redemption, representing the difference between the cash payment and the face value of Series B Notes redeemed net of the related derivative liabilities ($45,681 for the year ended March 31, 2024). As of March 31, 2025, there were no Series B Notes outstanding. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) As of March 31, 2025, and March 31, 2024, the Company recorded accrued interest in the amount of $88,881 and $88,602, respectively, related to the Series B Notes. During the years ended March 31, 2025, and March 31, 2024, the Company recognized interest expense in the amount of $279 and $3,739, respectively. Series C Convertible Notes The Company has issued Series C Notes of $1,812,700 (face value) by March 31, 2024, with net proceeds of $1,100,430 after payment of the relevant financing related fees. The Series C Notes were sold under subscription agreements to accredited investors. The Notes mature one year from the final closing date of the offering and accrue interest at 15% per annum. For Series C Notes, commencing six months following the Issuance Date, and at any time thereafter, at the sole election of the Holder, any amount of the outstanding principal and accrued interest of this note (the “Conversion Amount”) could be converted into that number of shares of Common Stock equal to: the Conversion Amount divided by the “Optional Conversion Price”, which is defined as lower of <span id="xdx_906_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zKRJh8hbjKOl" title="Description of conversion terms for debt instrument">(i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing (as defined in the Series C note agreements). For Series C Notes, “Mandatory Conversion” of the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty (20) consecutive Trading Days (the “Measurement Period”) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing. <span id="xdx_909_ecustom--PlacementAgentFeesDescription_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6qUfh9ZrE94" title="Placement agent fees description">The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company’s common shares at the time of final closing. <span id="xdx_909_ecustom--PlacementAgentFeesDescription_c20240401__20250331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_z8robZAYEXTh" title="Placement agent fees description">The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes. <span id="xdx_90B_ecustom--PlacementAgentFeesDescription_c20240401__20250331__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zxMbE8XP5Wsj">The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company’s common shares at the time final closing. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Prior to the final closing date (October 23, 2023), the Company determined that the conversion features contained in those Note, as well as the obligations to issue investor warrants and placement agent warrants represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion features, as well as the obligations related to investor warrant and placement agent warrant issuance. Subsequently, the exercise price of all warrants was concluded and locked to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231023__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--NoteHoldersMember_zKiOQuKCLFVb" title="Exercise Price">4.18 and $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231023__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentsWarrantsMember_zxDaWK90rHef" title="Exercise Price">2.09, respectively, for the note holder and placement agent warrants, as of the final closing date October 23, 2023. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of October 23, 2023 and then transferred to equity (collectively, “End of warrants derivative treatment”) in the amount of $1,278,786 (Note 8). For the Series C Notes, the Company recognized debt issuance costs of $207,361 during the year ended March 31, 2024 and treated these as debt discounts. The Company also recognized additional debt discount in the amount of $1,005,829 in connection with the recognition of derivative liabilities for the conversion features, investor warrants and placement agent warrants. The debt discounts are recorded as a contra liability against the convertible note and are amortized and recognized as accretion expenses using the effective interest method over the remaining lives of the Notes. During the year ended March 31, 2025, and March 31, 2024 the Company recognized discount amortization of $1,267,668 and $693,518, respectively, on Series C Notes as accretion and amortization expense. As of March 31, 2025 and March 31, 2024, the remaining unamortized discount on Series C convertible notes was $ nil and $1,232,274, respectively. During the year ended March 31, 2025, convertible notes with a face value of $1,487,700 and accrued interest of $237,230, were converted into 2,173,089 common shares. As of March 31, 2025, 577,644 shares are recognized as an obligation for shares to be issued relating to the conversions. The fair value of common shares issued during the year ended March 31, 2025 is $2,431,178, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $ 2,234,232, which consisted of the face value of notes converted, accrued interest of $237,230, and relevant derivative liability of $509,303. The Company recognized a loss upon conversion of $196,945, respectively, representing the difference between the value of debt settled and fair value of shares issued and to be issued. During the year ended March 31, 2025, convertible notes with a face value of $150,000 and accrued interest of $34,864, were redeemed for a cash payment of $184,864. The Company recorded a $nil gain on redemption related to the conversion, representing the difference between the value of the debt settled and the cash payment value. As of March 31, 2025, and March 31, 2024, the Company recorded accrued interest in the amount of $53,188 and $253,643, respectively, related to the Series C Notes. During the years ended March 31, 2025, and March 31, 2024, the Company recognized interest expense in the amounts of $70,712 and $251,045, respectively. Convertible Preferred Notes The Company entered into a convertible preferred note financing on September 25, 2023 and issued a convertible note (“Preferred Note”) for a principal amount of $1,000,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen (18) month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash monthly. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) The Company also issued a Preferred Note on October 25, 2023 in the principal amount of $250,000. The Preferred Note matures on the eighteen month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen month anniversary of the last closing date of the offering. The Preferred Note bears interest at a fixed rate of 12%, which is payable in cash quarterly. The Company issued a further Preferred Note in January 2024 for a principal amount of $114,303. The Preferred Note matures on the twenty-four (24) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the twenty-four month anniversary of the last closing date of the offering. The Preferred Note bears interest at a fixed rate of 8% which is payable in cash quarterly. The Company also issued a Preferred Note on June 17, 2024, for a principal amount of $300,000. The Preferred Note matures on the eighteen (18) month anniversary of the issuance date, or if there will be more than one closing pursuant to a qualified offering as defined in the financing agreement, the eighteen month anniversary of the last closing date of the offering (the “Maturity Date”). The Preferred Note bears interest at a fixed rate of 12% which is payable in cash quarterly. During the year ended March 31, 2025, the Company issued $1,985,000 in unsecured convertible promissory notes to private investors; $100,000 of the notes mature on their six-month anniversary of issuance and bear interest of 20%; $710,000 of the notes mature on their twenty four-month anniversary of issuance and bear interest of 10%; and $1,175,000 of the notes mature on their eighteen-month anniversary of issuance and bear not interest; all of the notes have conversion features that require the mutual consent of the investor and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Other Convertible Notes. As of March 31, 2025 and March 31, 2024, the Company recorded accrued interest in the amount of $36,163 and $4,103, respectively, related to the Preferred Notes. During the year ended March 31, 2025, the Company recognized interest expense in the amount of $180,888 (2024: $74,851). Other Convertible Notes On January 23, 2023, the Company issued $2,000,000 (face value) in convertible preferred notes (“the Notes”) to an accredited investor. The Notes mature 18 months from the issuance date. This note bears interest rate at a fixed rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230123__us-gaap--ShortTermDebtTypeAxis__custom--OtherConvertibleNotesPayableMember_zF6c0J8pZ0wj" title="Debt instrument interest rate stated percentage">10% in the form of stock with a striker price equal to the closing stock price on the note issuance date. Therefore, the Company issued <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesIssuanceOfSharesInLieuOfConvertibleNoteInterest_c20230123__20230123__us-gaap--ShortTermDebtTypeAxis__custom--OtherConvertibleNotesPayableMember_zhpAudAcGcP2" title="Convertible notes payable">45,045 units of common stock in lieu of interest on this convertible note. These stocks were valued at $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueIssuanceOfSharesInLieuOfConvertibleNoteInterest_c20230123__20230123__us-gaap--ShortTermDebtTypeAxis__custom--OtherConvertibleNotesPayableMember_zRIzpILcg5v9" title="Convertible notes payable">221,621 and was recognized as a deferred cost on the convertible note, recorded as a contra liability against the convertible note, and was amortized and recognized as accretion expense using the effective interest rate method over the remaining lives of the Notes. The conversion of the Notes is automatic upon a Qualified Financing which is in the control of the Company, or at maturity of the notes, upon mutual agreement by the noteholder and the Company. Since the conversion is not in control of the holder of the note, the Company did not recognize a derivative liability in connection with the conversion option of the Notes. As of March 31, 2024, the discount on Other Convertible Notes was fully amortized. As of March 31, 2023, the remaining unamortized discount on Other Convertible Notes was $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230331__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zexitiCOjrrf" title="Debt instrument unamortized discount">186,404. During the year ended March 31, 2025, and March 31, 2024 the Company recognized discount amortization of $nil and $186,404, respectively, on the Notes as accretion and amortization expense. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Other Short-term loans and Promissory Notes In December 2022, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromShortTermDebt_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_z0SUer2ZXyPl" title="Gross proceeds">400,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zG8BqsRTU7tf" title="Deferred finance costs">9,999. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is <span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtW_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zgYq88Fy8o74" title="Debt instrument term">40 weeks. The Company is required to make weekly payments of $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zUvyh5QLwZKf" title="Debt instrument periodic payment">13,995 ($<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zny8okV5kiq8" title="Debt instrument carrying amount">560,000 in the aggregate). As of March 31, 2024, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during the years ended March 31, 2025, and March 31, 2024 was $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zPCbFRskqAg9" title="Adjustment for amortization::XDX::-">nil and $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zTlVHqcDPFOj" title="Adjustment for amortization">6,142, respectively, and was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_90E_eus-gaap--AccretionExpense_dxL_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zwNpNSyQDLWi" title="Accretion expense::XDX::-">nil and $<span id="xdx_90A_eus-gaap--AccretionExpense_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zqDYSITKUYgj" title="Accretion expense">66,213 accretion expenses, during the years ended March 31, 2025, and March 31, 2024, respectively, related to the increase in present value of the loan over its term. For the year ended March 31, 2025, total repayments for the loan amounted to $<span id="xdx_901_eus-gaap--RepaymentsOfDebt_dxL_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zFzTLnoo52K6" title="Repayments of loan::XDX::-">nil. In December 2022, the Company also entered into a short-term collateralized bridge loan agreement with a finance company that advanced gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromShortTermDebt_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zJRqPbOi5ot5" title="Gross proceeds">800,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zS45eyXbTle4" title="Deferred finance costs">32,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of this second agreement is 40 weeks. The Company is required to make weekly payments of $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zzUzAvGAqsG2" title="Debt instrument payments">29,556 ($<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember__us-gaap--AwardDateAxis__custom--FirstFourWeeksMember_z6WtOAFs9Skl" title="Debt instrument payments">13,999 for the first four weeks, and $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_z953nXFtjCAi" title="Debt instrument carrying value">1,120,000 in the aggregate). As of March 31, 2024, the principal was fully repaid and discount for this loan was fully amortized. The discount amortization during years ended March 31, 2025, and March 31, 2024, was $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_dxL_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zrBwsKUheVmg" title="Adjustment for amortization::XDX::-">nil and $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zinMmnHp7RC1" title="Adjustment for amortization">20,800, respectively, which was recognized as part of the accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_901_eus-gaap--AccretionExpense_dxL_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zIy34bMBCDTd" title="Accretion expense::XDX::-">nil and $<span id="xdx_909_eus-gaap--AccretionExpense_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zIjWEDA6qNmd" title="Accretion expense">148,027 accretion expenses, during the years ended March 31, 2025, and March 31, 2024, respectively, related to the increase in present value of the loan over its term. As of March 31, 2025, total repayments for the loan amounted to $<span id="xdx_900_eus-gaap--RepaymentsOfDebt_dxL_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zYYBK4D7K3ui" title="Repayments of loan::XDX::-">nil. In December 2022, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $<span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_z3voaMV72vRj" title="Debt instrument carrying amount">600,000 (the “Principal Amount”). The note has a fixed rate of interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_z9P1cacvI2k7" title="Debt instrument interest rate during period">25% per annum payable monthly on the first day of every month. This promissory note matured on <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zTYAid2kYAG8" title="Maturity date">December 15, 2023, when the Principal Amount became due. The note has various default provisions which would, if triggered, result in the acceleration of the Principal Amount plus any accrued and unpaid interest. The note also has a <span id="xdx_905_ecustom--EarlyPaymentPenaltyProvisionPercentage_pid_dp_uPure_c20221201__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zdJXooY7lov7" title="Early payment penalty provision percentage">3% early payment penalty provision. As of March 31, 2025, and March 31, 2024, the amount of principal outstanding on the note was $<span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zVFfU68Rt2Dk" title="Debt instrument carrying amount"><span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zYJ8W3eZWF8f" title="Debt instrument carrying amount">600,000, and accrued interest outstanding on the note was $<span id="xdx_903_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zJAKVkkceei9" title="Interest payable">12,723 and $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zCVtUK5MVav1" title="Interest payable">12,723, respectively. The note continues to accrue interest, and no repayment demand notification was received from noteholder. During the years ended March 31, 2025, and March 21, 2024, the Company recorded interest expense in the amount of $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_z9H9nXYAqTx" title="Interest expense">150,000 and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorMember_zhD8Ly32gwmf" title="Interest expense">150,411, respectively, related to the promissory note. On December 30, 2022, the Company extinguished <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221230__srt--TitleOfIndividualAxis__custom--SeriesAConvertibleNoteHoldersMember_z5upQzmfOxlj" title="Warrants issued">51,101 warrants that were originally issued to Series A Convertible Noteholders and replaced these warrants with a new promissory note issued to the same warrant holder. The new promissory note has principal balance of $270,000, stated interest of zero, and maturity date of December 31, 2023. The fair value of this new promissory note was $248,479 as of the issuance date, which was calculated using a discount rate that was comparable to other loan issuance at the same time as well as the market bond rates at the time of the promissory note issuance. The difference between the fair value of the new note and its principal balance was $<span id="xdx_905_ecustom--AdjustmentCarryingValueAndPrincipalAmount_iI_c20221230__us-gaap--DebtInstrumentAxis__custom--NewPromissoryNoteMember_z6BxPIgCpy4j" title="Adjustment carrying value and principal amount">21,521, and was recognized as a discount, and amortized via effective interest rate method. The Company compared the fair value of the extinguished warrants immediately prior to extinguishment against the fair value of the new promissory note issued. As of March 31, 2025, the obligation to repay the principal balance at the original maturity date was waived for a finance charge of $50,000, which the Company recorded as interest expense in the in the statement of operations. As of March 31, 2025, the amount of principal outstanding on the note was $270,000, and the remaining unamortized discount was $nil. During years ended March 31, 2025, and March 31, 2024, the Company recognized amortization of discount on this promissory note in the amounts of $nil and $7,304, respectively, as accretion and amortization expenses. As of March 31, 2025, the Company recorded accrued interest in the amount of $50,000 related to this promissory note. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) On March 29, 2023, the Company entered into an additional collateralized bridge loan agreement with a finance company that advanced gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromShortTermDebt_c20230329__20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zFMjRLelOLo1" title="Gross proceeds">300,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_90D_eus-gaap--DeferredFinanceCostsNet_iI_c20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zXXrCiv9J4gg" title="Deferred finance costs">12,000. The issuance costs were recognized as a debt discount and would be amortized via the effective interest method. The term of this agreement is 40 weeks. The Company is required to make weekly payments of $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_c20230329__20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember__us-gaap--AwardDateAxis__custom--FirstFourWeeksMember_z3KNDRdkGUfg" title="Debt instrument periodic payment">5,250 for the first four weeks, and $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20230329__20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember__us-gaap--AwardDateAxis__custom--RemainingThirtySixWeeksMember_zYdc08d2gQe7" title="Debt instrument periodic payment">11,083 for the remaining 36 weeks, which is $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230329__us-gaap--DebtInstrumentAxis__custom--CollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zeYhq7Fehm6i" title="Long-term debt, gross">420,000 in aggregate. On July 18, 2023, the Company entered into an amendment with the finance company and increased total proceeds borrowed to $<span id="xdx_901_eus-gaap--ProceedsFromShortTermDebt_c20230718__20230718__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember_z4aaaBFnIT8h" title="Gross proceeds">700,000. The proceeds from the amended loan balance were netted against previously outstanding balance of the loan, along with an issuance cost in the amount of $<span id="xdx_901_eus-gaap--DeferredFinanceCostsNet_iI_c20230718__us-gaap--DebtInstrumentAxis__custom--SeriesANotesMember__dei--LegalEntityAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember_zCsl4CCr4ySg" title="Debt issuance costs in the amount">28,000. The term of this new loan agreement is 40 weeks. The Company is required to make weekly payments of $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_c20230718__20230718__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zX2SHWLjoySa" title="Debt instrument periodic payment">24,500, which is $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230718__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zqKArMGHWK37" title="Long-term debt, gross">980,000 in aggregate. The Company accounted for this amendment as a debt extinguishment and recognized a loss on the amendment of $<span id="xdx_904_ecustom--LossOnDebtAmendment_iI_c20230718__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zlbaHRSc4Sdc" title="Loss on amendment of debt">59,161 in other expenses. The issuance costs on the amended loan were recognized as a debt discount and would be amortized via the effective interest method. As of March 31, 2025, the amount of principal outstanding under this amended agreement was $<span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_dxL_c20250331__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zWdjyuIjXTf1" title="Debt instrument carrying value::XDX::-">nil and the remaining unamortized issuance cost discount was $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_dxL_c20250331__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zx9QIW7FV1Fb" title="Unamortized issuance cost discount::XDX::-">nil. During the year ended March 31, 2025, the Company recognized $<span id="xdx_90E_eus-gaap--AdjustmentForAmortization_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zdO5BfQfCjO" title="Adjustment for amortization">2,800 of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_90D_eus-gaap--AccretionExpense_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_z2aE9FpjmMVl" title="Accretion expense">4,152 accretion expenses, during the year ended March 31, 2025, related to the increase in present value of the loan over its term. During the year ended, net repayments for the loan amounted to $<span id="xdx_90B_eus-gaap--RepaymentsOfDebt_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--AdditionalCollateralizedBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--FinanceCompanyMember_zGz3jza7HEXb" title="Repayments of loan">191,500. In June 2023, the Company entered into a secured revolving account purchase credit and inventory financing facility (the “Revolving Facility”) with a revolving loan lender, pursuant to which the lender may from time to time purchase certain discrete account receivables from the Company (with full recourse) or may make loans and provide other financial accommodations, the payment of which are guaranteed and secured by certain assets of the Company. <span id="xdx_901_eus-gaap--LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription_c20230601__20230630_zFUMwGAGt3m4" title="Line of credit facility, revolving credit conversion to term loan, description">In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities. The inventory financing provided by this facility was limited to the lower of $0.3 million, or a 40% maximum of inventory balances. The Revolving Facility was accounted for as a secured borrowing. As of March 31, 2025, the Company had drawn $1,541,797 (2024: $1,286,792) in accounts receivable financing and $158,000 (2024: $125,000) in inventory financing with aggregate principal outstanding of $1,699,797 (2024: $1,411,792). During the year ended March 31, 2025, the Company recognized interest expense in the amount of $431,356 (2024: $263,696) As of March 31, 2025, the Company recorded accrued interest in the amount of $28,052 (2024: $23,879) related to the Revolving Facility. On July 13, 2023, the Company entered into another short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromShortTermDebt_c20230713__20230713__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zgy6x94UxbV3" title="Gross proceeds">400,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20230713__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_z18Ccn3nBJzb" title="Deferred finance costs">24,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is <span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtW_c20230713__20230713__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zhwkSEBG2nf9" title="Debt instrument term">14 weeks. The Company is required to make weekly payments of $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20230713__20230713__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zmiVvqDdOGQ" title="Debt instrument periodic payment">38,705 ($<span id="xdx_90C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230713__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_ziUpvM04VsUd" title="Debt instrument carrying amount">540,000 in the aggregate). As of March 31, 2025, the principal was fully repaid and discount for this loan was fully amortized. <span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_do_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zqAftxvO1gl9" title="Debt instrument periodic payment">No repayments were made during the year ended March 31, 2025. On August 11, 2023, the Company issued two short term promissory notes (“August 2023 Notes”), each for a principal amount of $250,000, to one investor for aggregate gross proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromShortTermDebt_c20230811__20230811__us-gaap--DebtInstrumentAxis__custom--TwoShortTermPromissoryNotesMember__dei--LegalEntityAxis__custom--OneInvestorMember_z31uPzk8IxU3" title="Proceeds from promissory notes">500,000. The August 2023 Notes do not accrue formal interest, but do contain administrative fees in the aggregate of $75,000. One of the notes matures three months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $25,000 is due. The second note matures six months from the issuance date upon which the principal amount of $250,000 and an administrative fee of $50,000 is due. The administrative fees were accrued as interest expenses for the period of the loans outstanding. As of March 31, 2025, the amount of principal outstanding on the note was $72,500, and accrued interest outstanding on the note was $75,000. On December 8, 2023, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromShortTermDebt_c20231208__20231208__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zfcTM1nFTYxc" title="Gross proceeds">630,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20231208__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_z3IrfRM01vW1" title="Deferred finance costs">15,750. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is <span id="xdx_900_eus-gaap--DebtInstrumentTerm_dtW_c20231208__20231208__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zQxgVKRvx74h" title="Debt instrument term">44 weeks. The Company is required to make weekly payments of $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_c20231208__20231208__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zcGG5qIq4Pi5" title="Debt instrument periodic payment">19,195 ($<span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231208__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zu39LbSOT7b2" title="Debt instrument carrying amount">844,200 in the aggregate). As of March 31, 2025, the amount of principal outstanding under this short-term bridge loan agreement was $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_dxL_c20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zyeDmHg3hQ75" title="Debt face amount::XDX::-">nil and the remaining unamortized issuance cost discount was $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_dxL_c20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zqOXVKHXxJFf" title="Unamortized issuance cost discount::XDX::-">nil. During the year ended March 31, 2025 the Company recognized $<span id="xdx_901_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zYEBWk5bY7Q9" title="Adjustment for amortization">10,023 (2024: $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zv7W8cxZ7m5f" title="Adjustment for amortization">5,727) of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_90A_eus-gaap--AccretionExpense_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zfUq0y7L8Tz6" title="Accretion expense">93,895 (2024: $<span id="xdx_90F_eus-gaap--AccretionExpense_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zQIT4d31ERT4" title="Accretion expense">120,305) accretion expenses during year ended March 31, 2025, related to the increase in present value of the loan over its term. As of March 31, 2025, total repayments for the loan amounted to $<span id="xdx_902_eus-gaap--RepaymentsOfDebt_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementOneMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyMember_zrn1KGJ0zm6f" title="Repayments of loan">570,425. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) During February 2024, the Company entered into a promissory note agreement with an individual investor that resulted in gross proceeds of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20240229__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zgMI5Nj5B2K4" title="Debt instrument carrying amount">660,504 (the “Principal Amount”). The note has a fixed rate of interest at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240201__20240229__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_z0M6ylURlnX" title="Debt instrument interest rate during period">12% per annum on the principle amount, payable monthly. As of March 31, 2025, the amount of principal outstanding on the note was $660,932, and accrued interest outstanding on the note was $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zINUEvRE8hR5" title="Interest payable">86,455 (2024: $<span id="xdx_90D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zOSZlI6snuo5" title="Interest payable">7,101). The note continues to accrue interest, and no repayment demand notification was received from note holder. During the year ended March 31, 2025, the Company recognized interest expense in the amount of $<span id="xdx_909_eus-gaap--InterestExpenseDebt_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zJIezQpmO3Wk" title="Interest expense">79,312 (2024: $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteAgreementMember__dei--LegalEntityAxis__custom--IndividualInvestorOneMember_zRZxrMZiGc88" title="Interest expense">7,131) related to the promissory note. On February 2, 2024, the Company entered into a short-term bridge loan agreement with a collateralized merchant finance company that advanced gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromShortTermDebt_c20240202__20240202__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zudtYR7uSJf1" title="Gross proceeds">700,000, prior to the deduction of issuance costs in the amount of $<span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_iI_c20240202__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zjFtJ6eSO5h6" title="Deferred finance costs">35,000. The issuance costs were recognized as a debt discount and amortized via the effective interest method. The term of the finance agreement is <span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtW_c20240202__20240202__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zb8G9aUC3YWd" title="Debt instrument term">35 weeks. The Company is required to make weekly payments of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_c20240202__20240202__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zBHQnnmYfZ24" title="Debt instrument periodic payment">29,235 ($<span id="xdx_907_eus-gaap--DebtInstrumentCarryingAmount_iI_c20240202__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_z0hNH8z8pWib" title="Debt instrument carrying amount">1,008,000 in the aggregate). As of March 31, 2025, the amount of principal outstanding under this agreement was $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_dxL_c20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zSoOBKaXT1xe" title="Debt face amount::XDX::-">nil and the remaining unamortized issuance cost discount was $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_dxL_c20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zuRkihbnZBI9" title="Unamortized issuance cost discount::XDX::-">nil. During the year ended March 31, 2025, the Company recognized $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zg5ulcebLZAh" title="Adjustment for amortization">26,879 (2024: $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20230401__20240331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_z9Sy9CeULtMe" title="Adjustment for amortization">8,121) of amortization of discount as accretion and amortization expenses. In addition, the Company recognized $<span id="xdx_908_eus-gaap--AccretionExpense_c20240401__20250331__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember_zZKSoGVyLRM9" title="Accretion expense">193,015 (2024: $<span id="xdx_909_eus-gaap--AccretionExpense_c20230401__20240331__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember_zQ0y5p6m9sCb" title="Accretion expense">114,985) accretion expenses during year ended March 31, 2025, related to the increase in present value of the loan over its term. As of March 31, 2025, total repayments for the loan amounted to $<span id="xdx_90A_eus-gaap--RepaymentsOfDebt_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--ShortTermBridgeLoanAgreementMember__dei--LegalEntityAxis__custom--CollateralizedMerchantFinanceCompanyOneMember_zXBTwWVw0pW7" title="Repayments of loan">745,305.

11275500

0.12

(i) the Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the 5 trading days prior to the Conversion Date (the conversion price).

the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.

24.00

0.75

the notes would automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price would be equal to the lower of $24.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company could, at its discretion, redeem the notes for 115% of their face value plus accrued interest.

The Company was obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a 3-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. The Company was obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,500 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes. The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series), with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing. On final closing, which occurred on January 8, 2021, the warrants’ exercise price was struck at $6.36 per share.

2301854

8088003

500000

121500

621500

0.12

0.75

821000

49393

272342

173762

98580

98850

1312500

The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion, redeem the notes for 115% of their face value plus accrued interest. The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage.

P3Y

6.36

100000

9.0

35417

1240000

10000

1312500

472500

34586

840000

555600

126833

126680

145682

The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note

24408

22009

25342

8320

135710

162851

18540

45681

88881

88602

279

3739

1812700

1100430

0.15

(i) seventy-five percent (75%) of the VWAP for the five (5) Trading Days prior to the Conversion Date, or (ii) eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing (as defined in the Series C note agreements).

the notes would convert into common stock at the applicable “Mandatory Conversion Price”, if either (i) on each of any twenty (20) consecutive Trading Days (the “Measurement Period”) (A) the closing price of the Common Stock on the applicable Trading Market is at least $18.00 per share and (B) the dollar value of average daily trades of the Common Stock on the applicable Trading Market is at least $400,000 per Trading Day; or (ii) upon the closing of a Qualified Financing, provided that the dollar value of average daily trades of the Common Stock on the applicable National Exchange on each of the ten (10) consecutive Trading Days following such closing is at least $400,000 per Trading Day. Mandatory Conversion Price means, in the case of a Mandatory Conversion under situation (i) above, seventy percent (70%) of the VWAP over the Measurement Period, or in the case of a Mandatory Conversion under situation (ii) above, eighty percent (80%) of the gross sale price per share of Common Stock (or conversion or exercise price per share of Common Stock of any Common Stock Equivalents) sold in a Qualified Financing.

The Company was obligated to issue warrants that accompany the convertible notes and provide 100% warrant coverage. The warrants have a 4-year term from date of issuance and an exercise price that is 200% of the 5-day volume weighted average price of the Company’s common shares at the time of final closing. The Company was obligated to pay the placement agent of the first series of Series C Notes a 10% cash fee for the face value of the notes. The Company was also obligated to issue warrants to the placement agent that have a 10-year term and cover 8% of face value of the notes, with an exercise price that equals to the 5-day volume weighted average price of the Company’s common shares at the time final closing.

4.18

2.09

1278786

207361

1005829

1267668

693518

1232274

1487700

237230

2173089

577644

2431178

2234232

237230

509303 196945

150000

34864

184864

53188

253643

70712

251045

1000000

0.12

250000

0.12

114303

0.08

300000

0.12

1985000

100000

0.20

710000

0.10

1175000

36163

4103

180888

74851

2000000

0.10

45045 221621

186404

400000

9999

P280D

13995

560000

6142

66213

800000

32000

29556

13999

1120000

20800

148027

600000

0.25

2023-12-15

0.03

600000

12723

150000

150411

51101

270000

2023-12-31

248479

21521 50000

270000

7304

50000

300000

12000

5250

11083

420000

700000

28000

24500

980000

59161

2800

4152

191500

In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities.

1200000

300000

1541797

1286792

158000

125000

1699797

1411792

431356

263696

28052

23879

400000

24000

P98D

38705

540000

250000

500000

75000

250000

25000

250000

50000

72500

75000

630000

15750

P308D

19195

844200

10023

5727

93895

120305

570425

660504

0.12

660932

86455

7101

79312

7131

700000

35000

P245D

29235

1008000

26879

8121

193015

114985

745305

6. TERM LOAN AND CREDIT AGREEMENT Term Loan On December 21, 2021, the Company entered into a Credit Agreement (“Credit Agreement”) with SWK Funding LLC (“Lender’); as part of this, the Company has borrowed $12.4 million, with a maturity date of December 21, 2026. The principal will accrue interest at the LIBOR Rate plus 10.5% per annum (subject to adjustment as set forth in the Credit Agreement). Interest payments are due each February, May, August and November commencing February 15, 2022. Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment. The negotiated terms indicate principal repayment of $2.4 million ($600,000 per quarter), during the final two years of the term. A current portion of the term loan of $2,400,000 was reported in the Company’s current liabilities as at December 31, 2024. Prepayment of amounts owing under the Credit Agreement is allowed under prescribed circumstances. Pursuant to the Credit Agreement the Company is subject to an Origination Fee in the amount of $120,000. Upon Termination of the Credit Agreement, the Company shall pay an Exit Fee, along with other fees that may be assessed during the term of the loan. As part of the loan transaction, the Company paid legal and professional costs directly in connection to the debt financing in the amount of $50,000 in cash. Total costs directly in connection to the debt financing in the amount of $193,437 (professional fee $48,484; lender’s origination fee, due diligence fee, and other expenses in the amount of $144,953) were deduced from the gross proceeds in the amount of $12,000,000. The Company also repaid $1,574,068 of existing short-term loan and promissory notes and relevant accrued interests by using the proceeds from the loan. Total costs directly in connection to the loan and fair value of warrants was in the amount of $1,042,149. And such costs were accounted for as debt discount and amortized using the effective interest method. The amortization of such debt discount was included in the accretion and amortization expenses. During November 2022, unpaid interest of $364,000 was added to the outstanding principal balance, since then interest onwards would be calculated on the updated principal balance. In connection with the Credit Agreement, the Company issued 57,536 warrants to the Lender, which were fair-valued at $198,713 at issuance (Note 9). The warrants were accounted as part of the debt discount as well as a credit into additional paid-in capital and amortized using the effective interest method. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) The Company and Lender also entered into a Guarantee and Collateral Agreement (“Collateral Agreement”) wherein the Company agreed to secure the Credit Agreement with all of the Company’s assets. The Company and Lender also entered into an Intellectual Property Security Agreement dated December 21, 2021 (the “IP Security Agreement”) wherein the Credit Agreement is also secured by the Company’s right title and interest in the Company’s Intellectual Property. In November 2024, the Company completed an additional transaction with its term lender to receive an additional $635 thousand in term loan proceeds, and interest relief through the capitalization of approximately $1.5 million in interest amounts due on its existing term loan. As part of this arrangement, the Company issued 600,000, 7-year share warrants to the term lender with a strike price of $0.50 per share and agreed to increase the term loan exit fee to $1.425 million at the end of its 5-year term. Concurrently, the Company received waiver and forbearance relief on certain term loan covenants and their respective defaults. The amortization of such debt discount was included in the accretion and amortization expenses. For the years ended March 31, 2025 and 2024, the amortization of debt discount expense was $356,778 and $206,224 respectively. Total interest expense on the term loan for the years ended March 31, 2025 and 2024 $2,180,897 and $1,981,054, respectively. During November 2024, the unpaid interest of $1.5 million was added to the outstanding principal balance, since then interest onwards would be calculated on the updated principal balance. The Company had accrued interest payable of $404,621 and $795,656, respectively, as of March 31, 2025 and March 31, 2024.

12400000

2026-12-21

0.105

2022-02-15

Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment.

2400000

600000

2400000

120000

50000

193437

48484

144953

12000000

1574068

1042149

364000

57536

198713

635000

1500000

600000

0.50

1425000

P5Y

356778

206224

2180897

1981054

1500000

404621

795656

7. FEDERALLY GUARANTEED LOAN Economic Injury Disaster Loan (“EIDL”) In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200430__us-gaap--DebtInstrumentAxis__custom--EconomicInjuryDisasterLoanMember_zGVW2BueAuUg" title="Debt interest rate">3.75% per annum, without the requirement for payment in its first 12 months. The Company may prepay the loan without penalty at will. In May 2021, the Company received an additional $499,900 from the SBA under the same terms. As of March 31, 2025, the Company recorded accrued interest of $Nil for the EIDL loan (March 31, 2024: $26,497). Interest expense on the above loan was $32,655 and $32,744 for the years ended March 31, 2025 and 2024, respectively.

370900

The loan has a term of 30 years and an interest rate of 3.75% per annum, without the requirement for payment in its first 12 months

P30Y

0.0375

499900

26497

32655

32744

8. DERIVATIVE LIABILITIES The Company analyzed the compound features of variable conversion and redemption embedded in the preferred shares instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value. A roll-forward of activity is presented below for the year ended March 31, 2025 and 2024: SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240401__20250331_zQ94GXnB6V31" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2025 $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230401__20240331_z05j5Xzg0sR5" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2024 $</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zHf5ukPudv3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Derivative liabilities, beginning of year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,435,668</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">759,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zqTalnqpzQEf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New issuance [Note 9]</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">649,533</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">964,446</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_z22YJys6LiIa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of derivatives during the year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">553,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(92,961</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ReductionDueToPreferredSharesConverted_z2kQKf97d4z5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Reduction due to preferred shares redeemed [Note 9]</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,159,692</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(194,882</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zyLT1GTlm44d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative liabilities, end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,478,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,435,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) The lattice methodology was used to value the derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Fiscal Year</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Fiscal Year</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dividend yield (%)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 16%; font-weight: bold; text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zvzku5xBSap5" title="Derivative liability, measurement input">12</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zIUYH3pSf3X4" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTdLU30Jw7Y9" title="Derivative liability, measurement input">3.7 – <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZwRIadW2txj" title="Derivative liability, measurement input">5.1 </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zrS8N7WWP9t3" title="Derivative liability, measurement input">4.7 – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztAfznWEEjFc" title="Derivative liability, measurement input">13.7 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zU8xRynsZNAf" title="Derivative liability, measurement input">91.2 – <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zj0hBIQe2LV8" title="Derivative liability, measurement input">194.2 </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z8nZaJWmSgsf" title="Derivative liability, measurement input">71.9 – <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zwk5BpETHn7d" title="Derivative liability, measurement input">119.1 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zW87WVkLtht" title="Derivative liability remaining term">0.17 – <span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6xQBxCi0md8" title="Derivative liability remaining term">2.0</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zLbuc04AEKxb" title="Derivative liability remaining term">0.25 – <span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zWr5deO42sGa" title="Derivative liability remaining term">2.01 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">0.24 – 1.34 </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.98 – 3.82 </td><td style="text-align: left"> </td></tr> </table> In addition, the Company recorded derivative liabilities related to the conversion and redemption features of the convertible notes, as well as warrants that were issued in connection with the convertible notes (Note 5). Any noteholder and placement agent warrants that were issued after the finalization of exercise price was accounted for as equity. <p id="xdx_890_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqFoHVpK5Q0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> SCHEDULE OF CONVERTIBLE NOTE AND WARRANT DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240401__20250331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zyOzZYsOkrq" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2025 $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230401__20240331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zwT13WmIGpca" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2024 $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zTP0EIlEAMce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic; text-align: left">Balance beginning of year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">991,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,008,216</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zaKjgCDewQ79" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New Issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,224,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConversionOfStockAmountConverted1_iN_di_zeHueqhjxJ34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(509,303</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(45,680</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--ConversionOfStockAmountRedemption_z68Rpk9eeb1i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible note redemption</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(59,011</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zrMQa2YiC05c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,184</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DerivativeTreatment_zaWFzuzZ4wxg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">End of derivative treatment of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,278,786</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConversionOfStockAmountModification_z4bMtsGdsBZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Convertible note modification</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_ztEtXtUKXIg1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left; padding-bottom: 2.5pt">Balance end of year</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">424,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">991,866</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zNjQAtblLMu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Monte-Carlo methodology was used to value the convertible note and warrant derivative components, using the following assumptions: SCHEDULE OF CONVERTIBLE NOTE AND WARRANT DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2TYM2rsa0b8" title="Derivative liability, measurement input">0.1 – <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMyDjkQrAQB5" title="Derivative liability, measurement input">5.2 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z7IR8BEvsbAh" title="Derivative liability, measurement input">4.2 – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBBSk1NVYBw9" title="Derivative liability, measurement input">5.3 </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z5oVtA0klric" title="Derivative liability, measurement input">91.2 – <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPkIvCt75zOk" title="Derivative liability, measurement input">194.4 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4jq4TTFTZe" title="Derivative liability, measurement input">76.2 – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zceQG0lQ1mQ7" title="Derivative liability, measurement input">126.6 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zG9JaR9lhKCi" title="Remaining terms">0.25 – <span id="xdx_903_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNRebBn6Je6l" title="Remaining terms">0.5 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zcMBbyuYH0dd" title="Remaining terms">0.25 – <span id="xdx_90E_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zRNhEv0ad8h6" title="Remaining terms">1.49 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--DerivativeStockPrice_iI_pid_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_zsqvtSqa9fH" title="Stock price">0.24 – <span id="xdx_901_ecustom--DerivativeStockPrice_iI_pid_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_zr6MNBYjEDRa" title="Stock price">1.45 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--DerivativeStockPrice_iI_pid_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_z08Mpqj4PvS" title="Stock price">1.08 – <span id="xdx_90A_ecustom--DerivativeStockPrice_iI_pid_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_zPPjjlLnNLWi" title="Stock price">4.20 </td><td style="text-align: left"> </td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars)

SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240401__20250331_zQ94GXnB6V31" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2025 $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230401__20240331_z05j5Xzg0sR5" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2024 $</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zHf5ukPudv3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Derivative liabilities, beginning of year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,435,668</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">759,065</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zqTalnqpzQEf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New issuance [Note 9]</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">649,533</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">964,446</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_z22YJys6LiIa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of derivatives during the year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">553,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(92,961</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ReductionDueToPreferredSharesConverted_z2kQKf97d4z5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Reduction due to preferred shares redeemed [Note 9]</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,159,692</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(194,882</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zyLT1GTlm44d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Derivative liabilities, end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,478,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,435,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1435668

759065

649533 964446

553208

-92961

-1159692 -194882

1478717

1435668

The lattice methodology was used to value the derivative components, using the following assumptions: SCHEDULE OF DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Fiscal Year</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Fiscal Year</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dividend yield (%)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 16%; font-weight: bold; text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zvzku5xBSap5" title="Derivative liability, measurement input">12</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zIUYH3pSf3X4" title="Derivative liability, measurement input">12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate for term (%)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTdLU30Jw7Y9" title="Derivative liability, measurement input">3.7 – <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZwRIadW2txj" title="Derivative liability, measurement input">5.1 </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zrS8N7WWP9t3" title="Derivative liability, measurement input">4.7 – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztAfznWEEjFc" title="Derivative liability, measurement input">13.7 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility (%)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zU8xRynsZNAf" title="Derivative liability, measurement input">91.2 – <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zj0hBIQe2LV8" title="Derivative liability, measurement input">194.2 </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z8nZaJWmSgsf" title="Derivative liability, measurement input">71.9 – <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zwk5BpETHn7d" title="Derivative liability, measurement input">119.1 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining terms (Years)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zW87WVkLtht" title="Derivative liability remaining term">0.17 – <span id="xdx_90C_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6xQBxCi0md8" title="Derivative liability remaining term">2.0</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zLbuc04AEKxb" title="Derivative liability remaining term">0.25 – <span id="xdx_90B_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zWr5deO42sGa" title="Derivative liability remaining term">2.01 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price ($ per share)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">0.24 – 1.34 </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.98 – 3.82 </td><td style="text-align: left"> </td></tr> </table>

3.7

5.1

4.7

13.7

91.2

194.2

71.9

119.1

P0Y2M1D P2Y P0Y3M P2Y3D 0.24 1.34 0.98 3.82

<p id="xdx_890_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqFoHVpK5Q0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> SCHEDULE OF CONVERTIBLE NOTE AND WARRANT DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240401__20250331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zyOzZYsOkrq" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2025 $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230401__20240331__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zwT13WmIGpca" style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year 2024 $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zTP0EIlEAMce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic; text-align: left">Balance beginning of year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">991,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,008,216</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue_zaKjgCDewQ79" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New Issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,224,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConversionOfStockAmountConverted1_iN_di_zeHueqhjxJ34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion to common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(509,303</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(45,680</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--ConversionOfStockAmountRedemption_z68Rpk9eeb1i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible note redemption</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(59,011</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zrMQa2YiC05c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,184</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DerivativeTreatment_zaWFzuzZ4wxg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">End of derivative treatment of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,278,786</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConversionOfStockAmountModification_z4bMtsGdsBZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Convertible note modification</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_ztEtXtUKXIg1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left; padding-bottom: 2.5pt">Balance end of year</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">424,200</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">991,866</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

991866

1008216

1224932

509303

45680

-59011

648

83184

-1278786

424200

991866

<p id="xdx_896_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zNjQAtblLMu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Monte-Carlo methodology was used to value the convertible note and warrant derivative components, using the following assumptions: SCHEDULE OF CONVERTIBLE NOTE AND WARRANT DERIVATIVE COMPONENTS VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free rate for term (%)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z2TYM2rsa0b8" title="Derivative liability, measurement input">0.1 – <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMyDjkQrAQB5" title="Derivative liability, measurement input">5.2 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z7IR8BEvsbAh" title="Derivative liability, measurement input">4.2 – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBBSk1NVYBw9" title="Derivative liability, measurement input">5.3 </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z5oVtA0klric" title="Derivative liability, measurement input">91.2 – <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPkIvCt75zOk" title="Derivative liability, measurement input">194.4 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4jq4TTFTZe" title="Derivative liability, measurement input">76.2 – <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zceQG0lQ1mQ7" title="Derivative liability, measurement input">126.6 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining terms (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zG9JaR9lhKCi" title="Remaining terms">0.25 – <span id="xdx_903_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20240401__20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNRebBn6Je6l" title="Remaining terms">0.5 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zcMBbyuYH0dd" title="Remaining terms">0.25 – <span id="xdx_90E_ecustom--DerivativeLiabilityRemainingTerm_dtY_c20230401__20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zRNhEv0ad8h6" title="Remaining terms">1.49 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price ($ per share)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--DerivativeStockPrice_iI_pid_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_zsqvtSqa9fH" title="Stock price">0.24 – <span id="xdx_901_ecustom--DerivativeStockPrice_iI_pid_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_zr6MNBYjEDRa" title="Stock price">1.45 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--DerivativeStockPrice_iI_pid_c20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_z08Mpqj4PvS" title="Stock price">1.08 – <span id="xdx_90A_ecustom--DerivativeStockPrice_iI_pid_c20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteAndWarrantDerivativeMember_zPPjjlLnNLWi" title="Stock price">4.20 </td><td style="text-align: left"> </td></tr> </table>

0.1

5.2

4.2

5.3

91.2

194.4

76.2

126.6

P0Y3M P0Y6M P0Y3M P1Y5M26D 0.24 1.45 1.08 4.20

9. STOCKHOLDERS’ DEFICIENCY AND MEZZANINE EQUITY (a) Authorized and Issued Stock As at March 31, 2025, the Company is authorized to issue 125,000,000 (March 31, 2024 – 125,000,000) shares of common stock ($0.001 par value), and 10,000,000 (March 31, 2024 – 10,000,000) shares of preferred stock ($0.001 par value), 20,000 of which (March 31, 2024 – 20,000) are designated shares of Series A preferred stock ($0.001 par value) and 600 (March 31, 2024 – 600) are designated shares of Series B preferred stock ($0.001 par value). At March 31, 2025, common shares and shares directly exchangeable into equivalent common shares that were issued and outstanding totaled <span id="xdx_904_eus-gaap--SharesOutstanding_iI_c20250331__srt--TitleOfIndividualAxis__custom--ShareholdersMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zI0xnz4625L6" title="Shares outstanding">26,241,967 (2024 – <span id="xdx_901_eus-gaap--SharesOutstanding_iI_c20240331__srt--TitleOfIndividualAxis__custom--ShareholdersMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zKj3cIWm4D7e" title="Shares outstanding">9,514,440) shares; these were comprised of 26,081,295 (2024 – 9,353,768) shares of common stock and 160,672 (2024 – 160,672) exchangeable shares. At March 31, 2025, there were 201 Series A shares of Preferred Stock that were issued and outstanding (2024 – 6,304), and there were 385 shares of Series B Preferred Stock that were issued and outstanding (March 31, 2024 – 180). There is also one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement and outstanding as at March 31, 2025 and 2024. (b) Series A Preferred Stock The number of Series A Preferred Stock issued and outstanding as of March 31, 2025 and 2024 was 201 and <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zaqMlUkKTJU1" title="Preferred stock, shares outstanding">6,304. The Series A Preferred Stock is junior to the Company’s existing undesignated preferred stock, and unless otherwise set forth in the applicable certificate of designations, shall be junior to any future issuance of preferred stock. The purchase price (the “Purchase Price”) for the Series A Preferred Stock to date has been $<span id="xdx_906_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5HRNtpRysA" title="Preferred stock, liquidation preference">100 per share. Except as otherwise expressly required by law, the Series A Preferred Stock does not have voting rights and does not have any liquidation rights. Preferred Stock Dividends Dividends shall be paid at the rate of <span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPo2WeNGCnj9" title="Preferred stock dividend rate percentage">12% per annum of the amount of the Series A Preferred Stockholder’s (the “Holder”) Purchase Price. Dividends shall be paid quarterly unless the Holder and the Company mutually agree to accrue and defer any such dividend. Conversion The Series A Preferred Stock is convertible into shares of common stock commencing 24 months after the issuance date of the Series A Preferred Stock. Upon which, on a monthly basis, up to <span id="xdx_90D_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNsyO7kLt5Id" title="Debt instrument redemption price percentage">5% of the aggregate amount of the Purchase Price can be converted (subject to adjustment for changes in the Holder’s ownership of the underlying Series A Preferred Stock). The conversion price is equal to the greater of $<span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbE0tnij6n9" title="Preferred stock convertible conversion price">.001 or a <span id="xdx_90A_ecustom--VolumeWeightedAveragePricePercentage_pid_dp_uPure_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zmaSzeNYXid9" title="Volume weighted average price percentage">15% discount to the volume-weighted average price (“VWAP”) of the Company’s common stock five Trading Days immediately prior to the conversion date (the “Conversion Rate). Additionally, subject to certain provisions, the Holder may exchange its Series A Preferred Stock into any common stock financing being conducted by the Company at a <span id="xdx_904_ecustom--VolumeWeightedAveragePricePercentage_pid_dp_uPure_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zx61h2pp6hFd" title="Volume weighted average price percentage">15% discount to the pricing of that financing. Other Adjustments and Rights <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● The Conversion Rate (and shares issuable upon conversion of the Series A Preferred Stock) will be appropriately adjusted to reflect stock splits, stock dividends business combinations and similar recapitalization.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● The Holders shall be entitled to a proportionate share of certain qualifying distributions on the same basis as if they were holders of the Company’s common stock on an as converted basis.</td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Company Redemption The Company may redeem all or part of the outstanding Series A Preferred Stock after one year from the date of issuance by paying an amount equal to the aggregate Purchase Price paid, adjusted for any reduction in Series A Preferred Stock holdings, multiplied by 110% plus accrued dividends During the year ended March 31, 2025, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 accrued dividends thereon were converted into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGAWswDOsbih" title="Debt conversion converted shares">8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion <span id="xdx_90C_eus-gaap--DepositLiabilitiesAccruedInterest_iNI_di_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2YrUfKzdka4" title="Deposit liabilities, accrued interest">($7,984,463), and the fair value of the common shares issued ($<span id="xdx_905_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zu9oDBqs1Il2" title="Stock redeemed or called during period, value">11,039,142), was $<span id="xdx_90D_eus-gaap--InvestmentCompanyDividendDistribution_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYj9nceosZfk" title="Investment company, dividend distribution">3,054,680 and was recognized as a deemed dividend expense. (c) Series B Preferred Stock and Mezzanine Equity On September 19, 2023, the Company entered into a security purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the issuance and sale of 220 shares of the Company’s newly designated Series B Convertible Preferred Stock, $0.001 par value (the “Series B Preferred Stock”), at a purchase price of $<span id="xdx_905_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8jiIfkSyhh" title="Preferred stock redemption price per share">9,091 per share of Preferred Stock, and after accounted for other issuance related costs, the net proceeds received was in the amount of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20230918__20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zY6rOGfMmbI7" title="Proceeds from issuance of preferred stock and preference stock"><span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20230918__20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKxRHKoRT8M6" title="Proceeds from issuance of preferred stock and preference stock">1,900,000. During the three months ended March 31, 2024, the Company issued an additional <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6nPOJftDgjj" title="Number of issued shares">110 Series B preferred shares were issued for net proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQdhnc9EJ68" title="Net proceeds from new issue value">925,000. During the three and nine months ended December 31, 2024, the Company issued an additional and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240401__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNxuRG16WdOh" title="Number of issued shares">220 Series B preferred shares for net proceeds of $ <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_dxL_c20241001__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zj3jPGQfXcef" title="Net proceeds from new issue value::XDX::-">nil and $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240401__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z3OAPanERRUi" title="Net proceeds from new issue value">1,732,532, respectively. Shares of Series B Preferred Stock and shares of Common Stock of the Company that are issuable upon conversion of, or as dividends on, the Series B Preferred Stock were offered and were issued pursuant to the Prospectus Supplement, filed September 19, 2023, to the Prospectus included in the Company’s Registration Statement on Form S-3 (Registration No. 333-255544) filed with the Securities and Exchange Commission on April 27, 2021, and declared effective May 4, 2021. Pursuant to the initial Purchase Agreement, on September 19, 2023, the Company filed a certificate of designations of Series B Convertible Preferred Stock (the “Certificate of Designations”) with the Nevada Secretary of State designating <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zEySW3mwIAEi" title="Preferred stock, shares issued">600 shares of the Company’s shares of Preferred Stock as Series B Convertible Preferred Stock and setting forth the voting and other powers, preferences and relative, participating, optional or other rights of the Preferred Shares. Each share of Series B Preferred Stock has a stated value of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCffh58EuD68" title="Preferred stock convertible conversion price">10,000 per share. The Series B Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company unless the holders of the majority of the outstanding shares of Series B Preferred Stock consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series B Preferred Stock. Holders of Series B Preferred Stock will be entitled to receive cumulative dividends (“Dividends”), in shares of common stock or cash on the stated value at an annual rate of <span id="xdx_90F_ecustom--StatedValuePercentage_iI_pid_dp_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKjVTt4XMKY8" title="Stated value percentage">8% (which will increase to <span id="xdx_90A_ecustom--StatedValuePercentage_iI_pid_dp_uPure_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zizex1BZ2Lsf" title="Stated value percentage">15% if a Triggering Event (as defined in the Certificate of Designations) occurs. Dividends will be payable upon conversion of the Series B Preferred Stock, upon any redemption, or upon any required payment upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations). Holders of Series B Preferred Stock will be entitled to convert shares of Series B Preferred Stock into a number of shares of common stock determined by dividing the stated value (plus any accrued but unpaid dividends and other amounts due) by the conversion price. The initial conversion price is $3.50, subject to adjustment in the event the Company sells common stock at a price lower than the then-effective conversion price. Holders may not convert the Series B Preferred Stock to common stock to the extent such conversion would cause such holder’s beneficial ownership of common stock to exceed <span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20230919__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--OwnershipAxis__custom--BeneficiaryMember_zDxxmDzVurH2" title="Ownership percentage">4.99% of the outstanding common stock. In addition, the Company will not issue shares of common stock upon conversion of the Series B Preferred Stock in an amount exceeding <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--OwnershipAxis__custom--BeneficiaryMember_zV6b2Qo8UXW7" title="Ownership percentage">19.9% of the outstanding common stock as of the initial issuance date unless the Company receives shareholder approval for such issuances. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount. The Series B Preferred Stock will automatically convert to common stock upon the 24-month anniversary of the initial issuance date of the Series B Preferred Stock. At any time after the earlier of a holder’s receipt of a Triggering Event notice and such holder becoming aware of a Triggering Event and ending on the 20th trading day after the later of (x) the date such Triggering Event is cured and (y) such holder’s receipt of a Triggering Event notice, such holder may require the Company to redeem such holder’s shares of Series B Preferred Stock. Upon any Bankruptcy Triggering Event (as defined in the Certificate of Designations), the Company will be required to immediately redeem all of the outstanding shares of Series B Preferred Stock. The Company will have the right at any time to redeem all or any portion of the Series B Preferred Stock then outstanding at a price equal to <span id="xdx_902_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20230918__20230919__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwJ2VTxiJBt3" title="Debt instrument redemption price percentage">110% of the stated value plus any accrued but unpaid dividends and other amounts due. Holders of the Series B Preferred Stock will have the right to vote on an as-converted basis with the common stock, subject to the beneficial ownership limitation set forth in the Certificate of Designations. The Series B Preferred Stock was accounted for as Mezzanine Equity in accordance with ASC 480 - Distinguishing Liabilities from Equity and the embedded conversion and redemption features was separated from the host instrument and recognized as derivative liabilities with change in fair value at each reporting period end recognized in the consolidated statement of operations and comprehensive loss. (Note 8). During the three months ended December 31, 2023, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z61P1Xfyvb86" title="Number of shares convertible securities">40 Series B preferred shares and dividends accrued thereon were converted into <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFi2li5cqirl" title="Number of shares convertible securities">612,062 common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $228,727 and reduced its accrued dividends liability by $16,789. The Company also reduced the fair value of derivative liabilities by $<span id="xdx_904_ecustom--ReductionDueToPreferredSharesRedeemed_c20231001__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z96sT8JnfOh" title="Fair value of derivative liabilities">119,359 in relation to related to the shares converted. The Company recognized corresponding credits to common share par value and paid in capital. During the three months ended March 31, 2024, <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zpHM6UCx4JWa" title="Preferred shares and dividends shares">25 Series B preferred shares and dividends accrued thereon were converted into 320,321 to be issued common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $142,908. The Company also reduced the fair value of derivative liabilities related to the shares converted by $ <span id="xdx_906_ecustom--ReductionDueToPreferredSharesRedeemed_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHVpmtDwSCj5" title="Fair value of derivative liabilities">75,523. The Company recognized corresponding credits to be issued common share par value and paid in capital. During the year ended March 31, 2025, 100 Series B preferred shares and dividends accrued thereon were converted into 3,650,361 common shares. As a result of the conversion, the Company reduced the book value of mezzanine equity by $571,629. The Company also reduced the fair value of derivative liabilities related to the shares converted by $351,214 related to the shares converted during the the year ended March 31, 2025. The Company recognized corresponding credits to be issued common shares. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) A roll-forward of activity is presented below for the year ended March 31, 2025: SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240401__20250331_zPfnPUOZMXsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230401__20240331_z2iXufVHj17d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--ConvertiblePreferredStock_iS_zxNQEF6FIphl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic">Balance beginning of year – March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,488,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_zCyZzi47dy63" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net proceeds received pursuant to the issuance of preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,825,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability_zjyIJEljFuua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Recognition of derivative liabilities (Note 8)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(649,533</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(964,446</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ConversionIntoCommonShares_zmLkKK2mU58b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Conversion into common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(571,629</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(371,634</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConvertiblePreferredStock_iE_zrE5ygtOLn59" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance end of year – March 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,488,920</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> (d) Share issuances Share issuances during the year ended March 31, 2025 During the three months and the year ended March 31, 2025, the Company issued <span id="xdx_90C_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_dxL_c20250101__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIce9aQ6yNxc" title="Issuance of common shares from shares to be issued::XDX::-">nil and <span id="xdx_908_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsHtAsHg5m65" title="Issuance of common shares from shares to be issued">320,321 common shares to Series B preferred shareholders, respectively, in relation to shares to be issued obligation as of March 2024 for Series B preferred share conversions. In October 2024, the Company issued 1,197,770 common shares on partial conversion of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20241001__20241031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertibleRedeemablePreferredStockMember_z5KtHp2lN1B1">25 shares of Series B Convertible Redeemable Preferred Stock, and a further 233,441 additional common shares required to complete its conversion obligation of a conversion of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240711__20240711__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertibleRedeemablePreferredStockMember_zOkO0Kpsa0lk">25 shares of Series B Convertible Redeemable Preferred Stock that was triggered on July 11, 2024. During the three and nine months ended December 31, 2024, the Company issued another 1,431,181 and 2,867,448 common shares to Series B preferred shareholders for an additional request to convert <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20241001__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7fgo5POg9M9" title="Number of conversion of shares">25 and <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSJSFjpuud5f" title="Number of conversion of shares">75 Series B preferred shares, respectively (see Note 9(c)). In addition, during the year ended March 31, 2025, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvvOoOFQFrNf" title="Common shares services">616,666 common shares for services received with a fair value of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zs5heN3Xbzv1" title="Issuance of warrants">292,596, which was recognized as a general and administrative expense with a corresponding credit to additional paid-in capital. During that same period, the Company issued 100,000 shares of common stock valued at $26,000 to a consultant as part of agreed contract remuneration In addition, the Company issued 480,000 common shares to an executive as part of a bonus compensation arrangement. The shares were issued in settlement of previously accrued bonus liabilities, with a total fair value of $206,400 recognized in the financial statements.During the year ended March 31, 2025, convertible notes with a face value of $1,487,700 were converted into 2,173,089 common shares. The fair value of common shares issued during the year ended March 31, 2025, is $2,431,178, and is determined based on market price upon conversion. Total value of debt settled is in the amount of $2,234,232, which consisted of the face value of notes converted, accrued interest of $237,230, and relevant derivative liability of $509,303. The Company recognized a loss upon conversion of $196,945, representing the difference between the value of debt settled and fair value of shares issued and to be issued. (Note 5). During the year ended March 31, 2025, $6,104,444 of Series A Preferred Stock (face value) and $1,071,542 relevant accrued dividend were converted into <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zV435mv200md" title="Debt conversion converted shares">8,952,170 common shares. The conversion was accounted as an extinguishment and the difference between the total carrying value of the preferred shares converted, derivative liabilities derecognized and unpaid dividend at the time of conversion <span id="xdx_90F_eus-gaap--DepositLiabilitiesAccruedInterest_iNI_di_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVcb4wTZs30g" title="Deposit liabilities, accrued interest">($7,984,463), and the fair value of the common shares issued ($<span id="xdx_90A_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zN3DyMiyAqah" title="Stock redeemed or called during period, value">11,039,142) was $<span id="xdx_90E_eus-gaap--InvestmentCompanyDividendDistribution_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZVXNTFISq8c" title="Investment company, dividend distribution">3,054,680 and was recognized as deemed dividend expense. The Company issued <span id="xdx_903_ecustom--IssuanceOfSharesForSettlementOfAccountsPayable_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmkzAlsQ4ya9" title="Issuance of shares for settlement of accounts payable">1,000,413 common shares in settlement of $<span id="xdx_902_ecustom--IssuanceOfSharesForSettlementOfAccountsPayableValue_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvjcytPYbA03" title="Issuance of shares for settlement of accounts payable, value">741,316 in amount due to a shareholder which was part of the accounts payable. The Company recognized a loss upon debt extinguishment of $249,093, which was the difference between the accounts payable settled and the fair value of common shares issued. The loss was included as part of the other income (expense) in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The Company issued 97,811 common shares for net proceeds of $125,227 pursuant to a registration statement filed on May 15, 2024. The Company issued 716,666 shares pursuant to the services provided by consultant (236,666 shares) and a director of the Company (480,000), and the fair of those shares were determined by using market value relative to the issuance. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Share issuances during the year ended March 31, 2024 The Company sold 36,897 common shares through use of its registration statement, for gross proceeds of $123,347, raising a net amount of $119,285 after paying for a 3% placement fee and other issuance expenses. In addition, 20,846 shares of common stock were issued to existing holders as a result of make whole provisions associated with the Reverse Split. (e) Shares to be issued During the year ended March 31, 2025, the Company issued <span id="xdx_906_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_dxL_c20241001__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleNoteMember_zNbekD2K8Oaf" title="Issuance of common shares from shares to be issued::XDX::-">nil common shares to Series C Note holders, in relation to shares to be issued obligation as of June 30, 2024, for Series C Note conversions. During the year ended March 31, 2025, the Company issued <span id="xdx_905_ecustom--IssuanceOfCommonSharesFromSharesToBeIssued_c20240401__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zAUbpDcrFJNi" title="Issuance of common shares from shares to be issued">320,321 common shares to Series B preferred shareholders in relation to shares to be issued obligation as of March 31, 2024, for Series B preferred share conversions. During the year ended March 31, 2025, Series C Notes with a face value of $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNmGvXblWh01" title="Instrument amount">1,487,700, were converted into <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240401__20250331__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zZrqyDJI90N" title="Converted instrument shares issued">2,173,089 common shares, respectively. As of March 31, 2025, <span id="xdx_909_ecustom--NumberOfObligationSharesToBeIssuedRelatedToConversion_iI_c20250331__us-gaap--DebtInstrumentAxis__custom--SeriesCNotesMember_zOpLCPMiJGxb" title="Number of obligation shares to be issued related to conversion">577,644 shares are recognized as an obligation for shares to be issued relating to the conversion. (f) Warrant issuances, exercises and other activity Warrant issuances during the year ended March 31, 2025 During the year ended March 31, 2025, the Company issued a 1,200,000 warrant to its executive against the stock options from the Company’s 2018 Equity Incentive Plan, with exercise price of 0.43. The Company recorded stock-based compensation of $422,456 under selling, general and administrative expenses with corresponding credit to additional paid in capital. In November 2024, the Company issued 600,000, 7-year share warrants to the term lender with a strike price of $0.50 per share with the fair value of 152,184 against an additional transaction with its term lender. The Company increased the liability with corresponding credit to additional paid in Capital. Warrant issuances during the year ended March 31, 2024 During the year ended March 31, 2024, the Company issued <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__custom--NoteHolderWarrantMember_zJdZQC3gt6Gk" title="Number of warrants issued">868,098 note holder warrants and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zt25XfWMnFzh" title="Number of warrants issued">69,062 placement agent warrants related to the final closing of Series C convertible notes (Note 5). These warrants relate to Series C Convertible Notes. Prior to the final closing date (October 23, 2023) of Series C Convertible Notes, the Company determined that the obligations to issue note holder warrants and placement agent warrants represented a derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities. Subsequently, the exercise price of all warrants was concluded and locked to $4.18 and $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zBCcToX8Wtmd" title="Exercise price">2.09, respectively, for the note holder and placement agent warrants, as of the final closing date October 23, 2023. Since the exercise price was no longer a variable, the Company concluded that the note holder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of October 23, 2023 and then transferred to equity (collectively, “End of warrants derivative treatment”). The warrants were therefore recognized with a reduction of $1,278,786 against the derivative liability and a corresponding credit against paid in capital. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) Warrant exercises and issuances during the year ended March 31, 2023 During the three months ended June 30, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220630__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsKPOqcP3hW5" title="Stock issued during period shares new issues">8,972 warrants as compensation to an executive of the Company who was not part of the Company stock options plan. The warrant expenses were fair-valued at $77,414, and recognized as general and administrative expenses, with a corresponding credit to additional paid-in capital. During the three months ended September 30, 2022, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220930__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXF8L4T4ilGb" title="Stock issued during period shares new issues">19,714 warrants as compensation to an executive of the Company who was not part of the Company stock options plan. The warrant expenses were fair-valued at $77,332, and recognized as general and administrative expenses, with a corresponding credit to additional paid-in capital. During the three months ended December 31, 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20221231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbgDk9MtLuwd" title="Stock issued during period shares new issues">36,463 warrants as compensation to an executive of the Company who was not part of the Company stock options plan. The fair value of the warrants at issuance was $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20221001__20221231__srt--TitleOfIndividualAxis__custom--ExecutiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9MuHnmAjXfi" title="Warrants and rights outstanding">77,780 and was recognized as a general and administrative expense, with a corresponding credit to additional paid-in capital. In addition, the Company added 52,083 warrants to its outstanding warrant schedule in connection with warrants issued to Series B convertible note holders. This has no impact on paid-in capital as the fair value of warrants was already accounted for as part of the original Series B convertible note issuance accounting entries. Lastly, the Company extinguished and exchanged <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCqbUD4R8Kt7" title="Warrants for promissory notes">51,101 warrants for promissory notes [Note 5] that resulted in an adjustment to additional paid-in capital in the amount of $71,768. Warrant issuances, exercises and expirations or cancellations during the fiscal years ended March 31, 2025 and 2024 as follows: Warrant activity during the years ended March 31, 2025 and 2024 is indicated below: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--BrokerWarrantsMember_zZpicmlsKM06" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Broker Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--ConsultantWarrantsMember_zqrIlzrzNqob" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consultant and Noteholder Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zf88Kqa35dGc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Issued on Convertible Notes</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_zt3F7UzlGt78" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43D_c20230401__20240331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zyP9Ti1CAIPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">As at March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">139,865</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">279,341</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">888,277</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1,307,483</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_z8BpGkp3YXte" style="vertical-align: bottom; background-color: White"> <td>Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(888,277</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(913,624</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_ztNuOL5EBp28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">69,062</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">868,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">937,160</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_437_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zDF2q6XfYXme" style="vertical-align: bottom; background-color: White"> <td>As at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zK96Vfec79wj" style="display: none; vertical-align: bottom; background-color: White"> <td>Beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zEk1ubLY3Ln5" style="vertical-align: bottom; background-color: White"> <td>Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zsmowGsMma4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_438_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_znMKTxngMNFh" style="vertical-align: bottom; background-color: White"> <td>As at March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">808,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,438,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,116,019</td><td style="text-align: left"> </td></tr> <tr id="xdx_436_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zxayj8ElDFj2" style="display: none; vertical-align: bottom; background-color: White"> <td>Ending balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">808,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,438,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,116,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXAQWPq4MRO5" title="Exercise Price">0.5 to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MaximumMember_zk0SmoPtDVrg" title="Exercise Price">22.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MinimumMember_ztd2rhm2ABTa" title="Exercise Price"> 0.43 to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MaximumMember_zsMyu34kRvYd" title="Exercise Price">14.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zychFJI1rCb9" title="Exercise Price">4.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zRnBDP8HGqKf" title="Expiration Date">August 2026 to October 2033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zJ7GBzbshMQ1" title="Expiration Date">March 2029 to Feb 2035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zlPPeGyYEIfh" title="Expiration Date">October 2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) (g) Stock-based compensation 2016 Equity Incentive Plan On February 2, 2016, the Board of Directors of the Company approved the Company’s 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards. The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20160202__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zKlDCErzj0a6" title="Share based payment award number of shares authorized">1,241,422 shares ; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 20% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase. During the year ended March 31, 2025, the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240401__20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zzP0eTHYqud6">2,836,176 stock options (2024:<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230401__20240331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zisxdIkD8IFk">7,210 options) with a weighted average grant date exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zhYZg7p7d5a">0.5 (2024: $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240331__us-gaap--PlanNameAxis__custom--TwoThousandAndSixteenEquityIncentivePlanMember_zdWVFDjkeOG4">2.774). The Company recorded stock-based compensation of $1,461,698 (2024: $1,025,930) under selling, general and administrative expenses with corresponding credit to additional paid in capital. During the year ended March 31,2025, the Company Cancelled stock options 931,000 of fair value $41,246 granted to its executive and reissued the stock options of 900,000 with the exercise price of 0.43 per share and fair value of 316,842. In addition to that Company also granted 1,936,176 The Company recorded stock based – compensation with the net amount of 275,596 under selling, general and administrative expenses with corresponding credit to additional paid in capital. The following table summarizes the stock option activities during the fiscal year ended March 31, 2025: SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value(1)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZH5FhYP8SCi" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Number of options, beginning outstanding">1,239,873</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZoJLWaeljs3" style="padding-bottom: 2.5pt; width: 10%; text-align: right" title="Weighted average exercise price, beginning outstanding">9.39</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 10%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDzaaRBsk769" title="Weighted average remaining contractual term beginning outstanding">5.35</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zpFvXXlTUSzc" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Aggregate intrinsic value, beginning outstanding">9,705,937</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adjustment for rounding effect of Reverse Split</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplit_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOfK1nxaFb83" style="text-align: right" title="Number of options, Adjustment for rounding effect of Reverse Split">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplitInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJYRfK53buma" style="text-align: right" title="Weighted average exercise price, Adjustment for rounding effect of Reverse Split">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEqC95hiXyBk" style="text-align: right" title="Number of options, Granted">2,836,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzdcbtj7Q4y3" style="text-align: right" title="Weighted average exercise price, Granted">0.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5MmdUHSMFzl" title="Weighted average remaining contractual term granted">0.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zas5lbI9gbHb" style="text-align: right" title="Number of options, Cancelled">(931,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ziRMbVZl8VSk" style="text-align: right" title="Weighted average exercise price, Cancelled">9.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyLOKa3Vhn04" title="Weighted average remaining contractual term Cancelled">4.24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zeo6YKSEsQU8" style="text-align: right" title="Number of options, Expired">(57,582</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zelmf3OGOUil" style="text-align: right" title="Weighted average exercise price, Expired">0.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpired2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfsHsJpw2hN5" title="Weighted average remaining contractual term, Expired">0.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcBbdpZpZuli" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(19,637</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcZj85mdXo7k" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Forfeited">0.37</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlPfeXQBbEpf" title="Weighted average remaining contractual term, Forfeited">2.34</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_za18VITKDUv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending outstanding">3,067,830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1Eb2ik5SVJ8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending outstanding">1.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZiTJ6Fpg1H8" title="Weighted average remaining contractual term, ending outstanding">1.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zJBf4EY58eMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending outstanding">1,078,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zK585HmjoQWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and expected to vest">3,067,830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJCPdH4e1qde" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and expected to vest">1.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRaJ9LjgXCpl" title="Weighted average remaining contractual term, Vested and expected to vest">1.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zcJ0OzStjj9c" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest">1,078,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and exercisable at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl48WooONsf1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and exercisable">2,611,411</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYXdNGv7cZG9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and exercisable">1.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zoxBBsHU7tk4" title="Weighted average remaining contractual term, Vested and exercisable">0.43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zPnQWhiaAaFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and exercisable">805,181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of March 31, 2025 and fair value of common stock adjusted.</td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) The following table summarizes the stock option activities during the fiscal year ended March 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value(1)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx76xCLZuKNc" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Number of options, beginning">1,264,890</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaKxxcvC4H75" style="padding-bottom: 2.5pt; width: 10%; text-align: right" title="Weighted average exercise price, beginning">9.29</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 10%; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znD3EZZVzBma" title="Weighted average remaining contractual term beginning">6.30</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zp8eek9sCx37" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Aggregate intrinsic value, beginning">8,185,321</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adjustment for rounding effect of Reverse Split</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplit_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCShZCJ0B1bb" style="text-align: right" title="Number of options, Adjustment for rounding effect of Reverse Split">12,655</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplitInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYlK9TDlcet6" style="text-align: right" title="Weighted average exercise price, Adjustment for rounding effect of Reverse Split">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z51tt5P0UWpj" style="text-align: right" title="Number of options, Granted">7,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZvswWqOAIV3" style="text-align: right" title="Weighted average exercise price, Granted">2.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdl8bqQhjjSd" title="Weighted average remaining contractual term granted">9.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcNqueMNTEn7" style="text-align: right" title="Number of options, Expired">(39,520</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJfy13ZoWvDi" style="text-align: right" title="Weighted average exercise price, Expired">3.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpired2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6VRUsauvt8d" title="Weighted average remaining contractual term expired">3.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztsAqrWmNU82" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(5,362</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zoVnq2oK8bs7" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Forfeited">12.30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAzRXi51U5s7" title="Weighted average remaining contractual term forfeited">8.85</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzHJbcACdCF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending">1,239,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4gjDIgJjaOg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending">9.39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9YeaNZs673j" title="Weighted average remaining contractual term ending">5.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zhxqwsrSMAF5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending">9,705,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSFru8Adosea" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and expected to vest">1,239,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYkdxKP8Lw01" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and expected to vest">9.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3Lohv4RGKC8" title="Weighted average remaining contractual term vested and expected to vest">5.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zcSBaaKGTVOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest">9,806,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMOF8ip8ZMuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and exercisable">1,134,642</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQIBTJAgrsP2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and exercisable">9.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdvudWMbIYY7" title="Weighted average remaining contractual term vested and exercisable">5.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_z3II7rEv4PTb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and exercisable">9,320,582</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of March 31, 2024 and fair value of common stock adjusted for the Reverse Split as of March 31, 2023 of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHb4xaNXRaUd" title="Fair value exercise price">1.48 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8alJejHz8kd" title="Fair value exercise price">2.81 per share, respectively.</td></tr> </table> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXkXcFqrBFr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective years ended March 31: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Exercise price ($)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MinimumMember_zhnWSL4nFDG9" title="Exercise price">0.43-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MaximumMember_z2D6T8Vjyf35" title="Exercise price">0.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.78</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zAmzNGxRLqPl" title="Risk free interest rate">4.24-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zFNhN5XhCQhl" title="Risk free interest rate">4.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.85</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zk5NAK9gEpRa" title="Expected term">1.46-<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zRFE1BdIwfij" title="Expected term">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zWV2GgA8HoE" title="Expected volatility">113.97-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zI7zk1Ihd4bb" title="Expected volatility">142.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20250331_zHHZCrWJDNZc" style="text-align: right" title="Expected dividend yield">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230401__20240331_zZinv80TBFe8" style="text-align: right" title="Expected dividend yield">0.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fair value of option ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MinimumMember_z6gXMQk7TLx3" title="Fair value of option">1.097-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MaximumMember_zISs0AOUJyhg" title="Fair value of option">1.360</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected forfeiture (attrition) rate (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20240401__20250331_zcW75kPMekC2" style="text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20230401__20240331_zvc3E1iqLsi3" style="text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="text-align: left"> </td></tr> </table> 2023 Equity Incentive Plan and the Employee Stock Purchase Plans On March 31, 2023, the Company adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan authorizes grants of equity-based and incentive cash awards to eligible participants designated by the 2023 Plan’s administrator. The 2023 Plan will be administered by the Compensation Committee of the Company’s Board of Directors (the “Board”). An aggregate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230331__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyThreeEquityIncentivePlanMember_zgeiLCRenNy5" title="Aggregate shares">5,000,000 shares of the Company’s common stock (the “Common Stock”), plus the number of shares available for issuance under the Company’s 2016 Equity Incentive Plan that had not been made subject to outstanding awards, were reserved for issuance under the 2023 Plan. Unless earlier terminated by the Board, the 2023 Plan will remain in effect until all Common Stock reserved for issuance has been issued, provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date of the 2023 Plan. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) The Company also adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP allows eligible employees of the Company and the Company’s designated subsidiaries the ability to purchase shares of the Company’s Common Stock at a discount, subject to various limitations. Under the ESPP, employees will be granted the right to purchase Common Stock at a discount during a series of successive offerings, the duration and timing of which will be determined by the ESPP administrator (the “Administrator”). In no event can any single offering period be longer than 27 months. The purchase price (the “Purchase Price”) for each offering will be established by the Administrator. With respect to an offering under Section 423 of the Internal Revenue Code of 1986 (“Section 423 Offering”), in no case may such Purchase Price be less than the lesser of (i) an amount equal to 85 percent of the fair market value on the commencement date, or (ii) an amount not less than 85 percent of the fair market value the on the purchase date. In the event of financial hardship, an employee may withdraw from the ESPP by providing a request at least 20 Business Days before the end of the offering period (the “Offering Period”). Otherwise, the employee will be deemed to have exercised the purchase right in full as of such exercise date. Upon exercise, the employee will purchase the number of whole shares that the participant’s accumulated payroll deductions will buy at the Purchase Price. If an employee wants to decrease the rate of contribution, the employee must make a request at least 20 Business Days before the end of an Offering Period (or such earlier date as determined by the Administrator). An employee may not transfer any rights under the ESPP other than by will or the laws of descent and distribution. During a participant’s lifetime, purchase rights under the ESPP shall be exercisable only by the participant.

125000000

0.001

10000000

0.001

20000

0.001

600

0.001

26241967

9514440

26081295

9353768

160672

201 201

6304

385

180

201 201

6304

100

0.12

0.05

0.001

0.15 0.15

1.10

6104444

1071542

8952170

7984463

11039142

3054680

220

0.001

9091

1900000

110

925000

220

1732532

600

10000

0.08 0.15 3.50

0.0499

0.199

Holders may elect to convert shares of Series B Preferred Stock to common stock at an alternate conversion price equal to 80% (or 70% if the Company’s common stock is suspended from trading on or delisted from a principal trading market or if the Company has effected a reverse split of the common stock) of the lowest daily volume weighed average price of the common stock during the Alternate Conversion Measuring Period (as defined in the Certificate of Designations). In the event the Company receives a conversion notice that elects an alternate conversion price, the Company may, at its option, elect to satisfy its obligation under such conversion with payment in cash in an amount equal to 110% of the conversion amount.

1.10

612062

228727

16789

119359

320321

142908 75523

100

3650361

571629

351214 A roll-forward of activity is presented below for the year ended March 31, 2025: SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240401__20250331_zPfnPUOZMXsi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230401__20240331_z2iXufVHj17d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_ecustom--ConvertiblePreferredStock_iS_zxNQEF6FIphl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; font-style: italic">Balance beginning of year – March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,488,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_zCyZzi47dy63" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net proceeds received pursuant to the issuance of preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,732,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,825,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability_zjyIJEljFuua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Recognition of derivative liabilities (Note 8)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(649,533</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(964,446</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ConversionIntoCommonShares_zmLkKK2mU58b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Conversion into common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(571,629</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(371,634</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ConvertiblePreferredStock_iE_zrE5ygtOLn59" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance end of year – March 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,000,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,488,920</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1488920

1732532

2825000

-649533 -964446 -571629 -371634 2000290 1488920 320321

1197770

233441

1431181

2867448

616666

292596

100000

26000

480000

206400

1487700

2173089

2431178

2234232

237230

509303 196945

6104444

1071542

8952170

7984463

11039142

3054680

1000413 741316 249093 97811 125227

716666

236666

480000

36897 123347

119285

0.03

20846

320321

1487700

2173089

577644

868098

69062

4.18

2.09

1278786

8972

77414

19714

77332

36463

77780

52083

51101

71768

Warrant activity during the years ended March 31, 2025 and 2024 is indicated below: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--BrokerWarrantsMember_zZpicmlsKM06" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Broker Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--ConsultantWarrantsMember_zqrIlzrzNqob" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consultant and Noteholder Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zf88Kqa35dGc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Issued on Convertible Notes</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_zt3F7UzlGt78" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43D_c20230401__20240331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zyP9Ti1CAIPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">As at March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">139,865</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">279,341</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">888,277</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1,307,483</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_z8BpGkp3YXte" style="vertical-align: bottom; background-color: White"> <td>Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(888,277</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(913,624</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_ztNuOL5EBp28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">69,062</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">868,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">937,160</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_437_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zDF2q6XfYXme" style="vertical-align: bottom; background-color: White"> <td>As at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_zK96Vfec79wj" style="display: none; vertical-align: bottom; background-color: White"> <td>Beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">253,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,331,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_zEk1ubLY3Ln5" style="vertical-align: bottom; background-color: White"> <td>Expired/cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(15,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_zsmowGsMma4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,800,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_438_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_znMKTxngMNFh" style="vertical-align: bottom; background-color: White"> <td>As at March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">808,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,438,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,116,019</td><td style="text-align: left"> </td></tr> <tr id="xdx_436_c20240401__20250331_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_zxayj8ElDFj2" style="display: none; vertical-align: bottom; background-color: White"> <td>Ending balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">808,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,438,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">868,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,116,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise Price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MinimumMember_zXAQWPq4MRO5" title="Exercise Price">0.5 to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember__srt--RangeAxis__srt--MaximumMember_zk0SmoPtDVrg" title="Exercise Price">22.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MinimumMember_ztd2rhm2ABTa" title="Exercise Price"> 0.43 to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember__srt--RangeAxis__srt--MaximumMember_zsMyu34kRvYd" title="Exercise Price">14.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zychFJI1rCb9" title="Exercise Price">4.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration Date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__custom--BrokerWarrantsMember_zRnBDP8HGqKf" title="Expiration Date">August 2026 to October 2033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__custom--ConsultantWarrantsMember_zJ7GBzbshMQ1" title="Expiration Date">March 2029 to Feb 2035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsIssuedOnConversionOfConvertibleNotesMember_zlPPeGyYEIfh" title="Expiration Date">October 2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>

139865

279341

888277

1307483

25347

888277

913624

69062

868098

937160

208927

253994

868098

1331019

208927

253994

868098

1331019

15000

600000

1200000

1800000

808927

1438994

868098

3116019

808927

1438994

868098

3116019

0.5

22.5

0.43

14.40

4.18

August 2026 to October 2033

March 2029 to Feb 2035

October 2027

1241422

2836176

7210

0.5

2.774

1461698

1025930

931000

The following table summarizes the stock option activities during the fiscal year ended March 31, 2025: SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value(1)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZH5FhYP8SCi" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Number of options, beginning outstanding">1,239,873</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZoJLWaeljs3" style="padding-bottom: 2.5pt; width: 10%; text-align: right" title="Weighted average exercise price, beginning outstanding">9.39</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 10%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDzaaRBsk769" title="Weighted average remaining contractual term beginning outstanding">5.35</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zpFvXXlTUSzc" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Aggregate intrinsic value, beginning outstanding">9,705,937</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adjustment for rounding effect of Reverse Split</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplit_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOfK1nxaFb83" style="text-align: right" title="Number of options, Adjustment for rounding effect of Reverse Split">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplitInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJYRfK53buma" style="text-align: right" title="Weighted average exercise price, Adjustment for rounding effect of Reverse Split">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEqC95hiXyBk" style="text-align: right" title="Number of options, Granted">2,836,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzdcbtj7Q4y3" style="text-align: right" title="Weighted average exercise price, Granted">0.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5MmdUHSMFzl" title="Weighted average remaining contractual term granted">0.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zas5lbI9gbHb" style="text-align: right" title="Number of options, Cancelled">(931,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ziRMbVZl8VSk" style="text-align: right" title="Weighted average exercise price, Cancelled">9.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermCancelled_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyLOKa3Vhn04" title="Weighted average remaining contractual term Cancelled">4.24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zeo6YKSEsQU8" style="text-align: right" title="Number of options, Expired">(57,582</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zelmf3OGOUil" style="text-align: right" title="Weighted average exercise price, Expired">0.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpired2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfsHsJpw2hN5" title="Weighted average remaining contractual term, Expired">0.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcBbdpZpZuli" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(19,637</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcZj85mdXo7k" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Forfeited">0.37</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlPfeXQBbEpf" title="Weighted average remaining contractual term, Forfeited">2.34</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_za18VITKDUv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending outstanding">3,067,830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1Eb2ik5SVJ8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending outstanding">1.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZiTJ6Fpg1H8" title="Weighted average remaining contractual term, ending outstanding">1.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zJBf4EY58eMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending outstanding">1,078,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zK585HmjoQWe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and expected to vest">3,067,830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJCPdH4e1qde" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and expected to vest">1.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRaJ9LjgXCpl" title="Weighted average remaining contractual term, Vested and expected to vest">1.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zcJ0OzStjj9c" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest">1,078,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and exercisable at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl48WooONsf1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and exercisable">2,611,411</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYXdNGv7cZG9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and exercisable">1.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zoxBBsHU7tk4" title="Weighted average remaining contractual term, Vested and exercisable">0.43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zPnQWhiaAaFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and exercisable">805,181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of March 31, 2025 and fair value of common stock adjusted.</td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) The following table summarizes the stock option activities during the fiscal year ended March 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value(1)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; padding-bottom: 2.5pt">Outstanding at March 31, 2023</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx76xCLZuKNc" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Number of options, beginning">1,264,890</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaKxxcvC4H75" style="padding-bottom: 2.5pt; width: 10%; text-align: right" title="Weighted average exercise price, beginning">9.29</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 2.5pt; width: 10%; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znD3EZZVzBma" title="Weighted average remaining contractual term beginning">6.30</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zp8eek9sCx37" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Aggregate intrinsic value, beginning">8,185,321</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Adjustment for rounding effect of Reverse Split</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplit_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCShZCJ0B1bb" style="text-align: right" title="Number of options, Adjustment for rounding effect of Reverse Split">12,655</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentForRoundingEffectOfReverseSplitInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYlK9TDlcet6" style="text-align: right" title="Weighted average exercise price, Adjustment for rounding effect of Reverse Split">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z51tt5P0UWpj" style="text-align: right" title="Number of options, Granted">7,210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZvswWqOAIV3" style="text-align: right" title="Weighted average exercise price, Granted">2.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdl8bqQhjjSd" title="Weighted average remaining contractual term granted">9.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcNqueMNTEn7" style="text-align: right" title="Number of options, Expired">(39,520</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJfy13ZoWvDi" style="text-align: right" title="Weighted average exercise price, Expired">3.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpired2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6VRUsauvt8d" title="Weighted average remaining contractual term expired">3.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztsAqrWmNU82" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(5,362</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zoVnq2oK8bs7" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, Forfeited">12.30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermForfeited2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAzRXi51U5s7" title="Weighted average remaining contractual term forfeited">8.85</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzHJbcACdCF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending">1,239,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4gjDIgJjaOg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending">9.39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9YeaNZs673j" title="Weighted average remaining contractual term ending">5.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zhxqwsrSMAF5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, ending">9,705,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSFru8Adosea" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and expected to vest">1,239,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYkdxKP8Lw01" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and expected to vest">9.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3Lohv4RGKC8" title="Weighted average remaining contractual term vested and expected to vest">5.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_zcSBaaKGTVOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and expected to vest">9,806,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMOF8ip8ZMuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Vested and exercisable">1,134,642</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQIBTJAgrsP2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, Vested and exercisable">9.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdvudWMbIYY7" title="Weighted average remaining contractual term vested and exercisable">5.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230401__20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_fKDEp_z3II7rEv4PTb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Vested and exercisable">9,320,582</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of March 31, 2024 and fair value of common stock adjusted for the Reverse Split as of March 31, 2023 of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHb4xaNXRaUd" title="Fair value exercise price">1.48 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUSUVTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8alJejHz8kd" title="Fair value exercise price">2.81 per share, respectively.</td></tr> </table>

1239873

9.39

P5Y4M6D

9705937

2836176

0.5

P0Y7D -931000 9.32 P4Y2M26D

57582

0.56

P0Y2M1D

19637

0.37

P2Y4M2D

3067830

1.14

P1Y9M7D

1078756

3067830

1.14

P1Y9M7D

1078756

2611411

1.17

P0Y5M4D

805181

1264890

9.29

P6Y3M18D

8185321

12655

7210

2.77

P9Y3D

39520

3.89

P3Y9M3D

5362

12.30

P8Y10M6D

1239873

9.39

P5Y4M6D

9705937

1239873

9.32

P5Y4M6D

9806024

1134642

9.62

P5Y1M6D

9320582

1.48

2.81

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXkXcFqrBFr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of each option granted is estimated at the time of grant using multi-nominal lattice model using the following assumptions, for each of the respective years ended March 31: SCHEDULE OF FAIR VALUE OF OPTION GRANTED USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Exercise price ($)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MinimumMember_zhnWSL4nFDG9" title="Exercise price">0.43-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MaximumMember_z2D6T8Vjyf35" title="Exercise price">0.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.78</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zAmzNGxRLqPl" title="Risk free interest rate">4.24-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zFNhN5XhCQhl" title="Risk free interest rate">4.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.85</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zk5NAK9gEpRa" title="Expected term">1.46-<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zRFE1BdIwfij" title="Expected term">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MinimumMember_zWV2GgA8HoE" title="Expected volatility">113.97-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240401__20250331__srt--RangeAxis__srt--MaximumMember_zI7zk1Ihd4bb" title="Expected volatility">142.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240401__20250331_zHHZCrWJDNZc" style="text-align: right" title="Expected dividend yield">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230401__20240331_zZinv80TBFe8" style="text-align: right" title="Expected dividend yield">0.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Fair value of option ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MinimumMember_z6gXMQk7TLx3" title="Fair value of option">1.097-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250331__srt--RangeAxis__srt--MaximumMember_zISs0AOUJyhg" title="Fair value of option">1.360</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected forfeiture (attrition) rate (%)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20240401__20250331_zcW75kPMekC2" style="text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ExpectedForfeitureAttritionRates_pid_dp_uPure_c20230401__20240331_zvc3E1iqLsi3" style="text-align: right" title="Expected forfeiture (attrition) rate">0.00</td><td style="text-align: left"> </td></tr> </table>

0.43

2.78

0.0424

0.0433

0.0385

P1Y5M15D

P5Y

P10Y

1.1397

1.4222

1.171

0.0000

1.097

1.360

2.3

0.0000 0.0000

5000000

10. INCOME TAXES Income taxes The provision for income taxes differs from that computed at combined corporate tax rate of approximately 26% as follows: Income tax recovery SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240401__20250331_zE33RtfPt6X7" style="border-bottom: Black 1pt solid; text-align: center">Year ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230401__20240331_zOmx9KYqm3fj" style="border-bottom: Black 1pt solid; text-align: center">Year ended March 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zyLx1YRnE9Ld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Net loss</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(8,421,179</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(14,094,283</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_iN_di_msITEBzZam_zzqOB42GGml6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected income tax recovery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,189,707</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,664,514</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzZam_zeZ1P2kF9u0k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,322,198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">882,745</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzZam_zoRiXSbyARUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other temporary differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(988</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,160</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzZam_ztMjM74UujO9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">868,297</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,785,929</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzZam_zH2IwPUQECR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Income tax recovery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Deferred tax assets SCHEDULE OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250331_zcDkxZG4hBrj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As at March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240331_zT60Ix7fNDG1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As at March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pp0p0_maDTANzytD_zxZpxREgkf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Non-capital loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">19,078,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">18,211,344</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTANzytD_zRoxmW4954bf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other temporary differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,803</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,963</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzytD_zGgmLOFUlm53" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(19,082,456</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(18,219,307</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzytD_z3XEgvDgougl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) As of March 31, 2025 and 2024, the Company decided that a valuation allowance relating to the above deferred tax assets of the Company was necessary, largely based on the negative evidence represented by losses incurred and a determination that it is not more likely than not to realize these assets, such that, a corresponding valuation allowance, for each respective period, was recorded to offset deferred tax assets. As of March 31, 2025 and 2024, the Company has approximately $73,379,434 and $70,043,631, respectively, of non-capital losses available to offset future taxable income. These losses will expire between 2035 to 2039. As of March 31, 2025, and 2024 the Company was not subject to any uncertain tax positions.

Income tax recovery SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240401__20250331_zE33RtfPt6X7" style="border-bottom: Black 1pt solid; text-align: center">Year ended March 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230401__20240331_zOmx9KYqm3fj" style="border-bottom: Black 1pt solid; text-align: center">Year ended March 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zyLx1YRnE9Ld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Net loss</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(8,421,179</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(14,094,283</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_iN_di_msITEBzZam_zzqOB42GGml6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected income tax recovery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,189,707</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,664,514</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzZam_zeZ1P2kF9u0k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,322,198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">882,745</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzZam_zoRiXSbyARUa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other temporary differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(988</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,160</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzZam_ztMjM74UujO9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">868,297</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,785,929</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzZam_zH2IwPUQECR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Income tax recovery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

-8421179

-14094283

2189707

3664514

1322198

882745

-988

-4160

868297

2785929

Deferred tax assets SCHEDULE OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250331_zcDkxZG4hBrj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As at March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240331_zT60Ix7fNDG1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As at March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_iI_pp0p0_maDTANzytD_zxZpxREgkf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Non-capital loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">19,078,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">18,211,344</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTANzytD_zRoxmW4954bf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other temporary differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,803</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,963</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzytD_zGgmLOFUlm53" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(19,082,456</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(18,219,307</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzytD_z3XEgvDgougl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

19078653

18211344

3803

7963

19082456

18219307

73379434

70043631

These losses will expire between 2035 to 2039.

11. COMMITMENTS AND CONTINGENCIES There are no claims against the Company that were assessed as significant, which were outstanding as at March 31, 2025 and, consequently, no provision for such has been recognized in the consolidated financial statements.

12. OPERATING LEASE RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS The Company has one operating lease primarily for office and administration. During December 2021, the Company entered into a new lease agreement. The Company paid $85,000 deposit that would be returned at the end of the lease. In December 2022, the Company started a new lease with an additional suite in the same premise as the existing lease. When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate. The weighted-average-rate applied is 11.4%. SCHEDULE OF OPERATING LEASES OBLIGATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="text-align: center">2024</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Right of Use Asset</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20240401__20250331_zqwyqrPzNk7d" style="width: 16%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,221,593</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20230401__20240331_zxFhj1hysbbc" style="width: 16%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,587,492</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20240401__20250331_zb8sipROAAJc" style="text-align: right" title="Right of use asset, new leases">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20230401__20240331_z5g5QxQsRQtd" style="text-align: right" title="Right of use asset, new leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20240401__20250331_zYilbJzMyKyg" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(409,540</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20230401__20240331_zFNVLZjeyey1" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(365,899</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at March 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20240401__20250331_zBHDTVIjjwG7" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">812,053</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20230401__20240331_zakcovLOP6oj" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,221,593</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="text-align: center">2024</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Lease Liability</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseLiability_iS_c20240401__20250331_z0hJXo4BBnsl" style="width: 16%; text-align: right" title="Operating lease liability, beginning balance">1,386,486</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_iS_c20230401__20240331_z52UgpvILmGj" style="width: 16%; text-align: right" title="Operating lease liability, beginning balance">1,722,095</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--OperatingLeaseNewLeases_c20240401__20250331_zVnmK5nlN6Jb" style="text-align: right" title="Lease liability, new leases">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--OperatingLeaseNewLeases_c20230401__20240331_zIwQahw9fZ9l" style="text-align: right" title="Lease liability, new leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Repayment and interest accretion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20240401__20250331_zOxrj92cp1Q9" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion">(457,370</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20230401__20240331_zHWKGk6guBG5" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion">(335,609</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at March 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_c20240401__20250331_zu7NgLek9kgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">929,116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_iE_c20230401__20240331_z2uGMKthqMVc" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,386,486</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20250331_zHioFt3n7Nfb" style="text-align: right" title="Current portion of operating lease liability">531,286</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20240331_zsZsH14YWmH1" style="text-align: right" title="Current portion of operating lease liability">457,371</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noncurrent portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20250331_zq1ZnyHec7Kf" style="text-align: right" title="Noncurrent portion of operating lease liability">397,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20240331_zJULFVYfvria" style="text-align: right" title="Noncurrent portion of operating lease liability">929,115</td><td style="text-align: left"> </td></tr> </table> The operating lease expense was $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zEE8aVRT6SDb" title="Operating lease expense">587,045 for the year ended March 31, 2025 (2024: $<span id="xdx_902_eus-gaap--OperatingLeaseExpense_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z3Q6Gref2V8a" title="Operating lease expense">564,167) and included in the selling, general and administrative expenses. Operating cash flows from operating leases amounted to $587,164 and $509,041 during the years ended March 31, 2025 and March 31, 2024, respectively. BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars) <p id="xdx_89B_ecustom--ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock_znFD08KQdK9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table represents the contractual undiscounted cash flows for lease obligations as at March 31, 2025: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Calendar year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250331_z6tI8fxExKce" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzTPy_maLOLLPzpEs_zBnGwyZLQPKc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">600,288</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzTPy_maLOLLPzpEs_zcJYfEGzTBQ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,360</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndBeyond_iI_maLOLLPzTPy_maLOLLPzpEs_z5GFfIhRDaf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027 and beyond</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzpEs_zlXFRvIRmxlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,165,648</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQMLt6Kp9ael" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(236,532</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zR6APW7Kkq0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">929,116</td><td style="text-align: left"> </td></tr> </table>

85000

SCHEDULE OF OPERATING LEASES OBLIGATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="text-align: center">2024</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Right of Use Asset</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20240401__20250331_zqwyqrPzNk7d" style="width: 16%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,221,593</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20230401__20240331_zxFhj1hysbbc" style="width: 16%; text-align: right" title="Operating lease right-of-use asset, beginning balance">1,587,492</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20240401__20250331_zb8sipROAAJc" style="text-align: right" title="Right of use asset, new leases">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeaseRightOfUseAssetNewLeases_c20230401__20240331_z5g5QxQsRQtd" style="text-align: right" title="Right of use asset, new leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20240401__20250331_zYilbJzMyKyg" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(409,540</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20230401__20240331_zFNVLZjeyey1" style="border-bottom: Black 1pt solid; text-align: right" title="Right of use asset, amortization">(365,899</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at March 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20240401__20250331_zBHDTVIjjwG7" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">812,053</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20230401__20240331_zakcovLOP6oj" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use asset, ending balance">1,221,593</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="text-align: center">2024</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Lease Liability</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Beginning balance at March 31</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingLeaseLiability_iS_c20240401__20250331_z0hJXo4BBnsl" style="width: 16%; text-align: right" title="Operating lease liability, beginning balance">1,386,486</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_iS_c20230401__20240331_z52UgpvILmGj" style="width: 16%; text-align: right" title="Operating lease liability, beginning balance">1,722,095</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--OperatingLeaseNewLeases_c20240401__20250331_zVnmK5nlN6Jb" style="text-align: right" title="Lease liability, new leases">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--OperatingLeaseNewLeases_c20230401__20240331_zIwQahw9fZ9l" style="text-align: right" title="Lease liability, new leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Repayment and interest accretion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20240401__20250331_zOxrj92cp1Q9" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion">(457,370</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--OperatingLeaseRepaymentAndInterestAccretion_iN_di_c20230401__20240331_zHWKGk6guBG5" style="border-bottom: Black 1pt solid; text-align: right" title="Lease liability, repayment and interest accretion">(335,609</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Ending balance at March 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_c20240401__20250331_zu7NgLek9kgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">929,116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingLeaseLiability_iE_c20230401__20240331_z2uGMKthqMVc" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability, ending balance">1,386,486</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20250331_zHioFt3n7Nfb" style="text-align: right" title="Current portion of operating lease liability">531,286</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20240331_zsZsH14YWmH1" style="text-align: right" title="Current portion of operating lease liability">457,371</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noncurrent portion of operating lease liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20250331_zq1ZnyHec7Kf" style="text-align: right" title="Noncurrent portion of operating lease liability">397,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20240331_zJULFVYfvria" style="text-align: right" title="Noncurrent portion of operating lease liability">929,115</td><td style="text-align: left"> </td></tr> </table>

1221593

1587492

409540

365899

812053

1221593

1386486

1722095

457370 335609

929116

1386486

531286

457371

397830

929115

587045

564167

587164

509041

<p id="xdx_89B_ecustom--ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationTableTextBlock_znFD08KQdK9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table represents the contractual undiscounted cash flows for lease obligations as at March 31, 2025: SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Calendar year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250331_z6tI8fxExKce" style="border-bottom: Black 1pt solid; text-align: center">$</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzTPy_maLOLLPzpEs_zBnGwyZLQPKc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">600,288</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzTPy_maLOLLPzpEs_zcJYfEGzTBQ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565,360</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndBeyond_iI_maLOLLPzTPy_maLOLLPzpEs_z5GFfIhRDaf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027 and beyond</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzpEs_zlXFRvIRmxlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,165,648</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQMLt6Kp9ael" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(236,532</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_zR6APW7Kkq0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">929,116</td><td style="text-align: left"> </td></tr> </table>

600288

565360

1165648

236532

929116

13. PROPERTY AND EQUIPMENT During the year-ended March 31, 2022, the Company purchased leasehold improvements of $12,928 (useful life: <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z9pZvWgPs7Qe" title="Leasehold improvements useful life">5 years) as well as furniture & fixtures of $16,839 (useful life: <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zgIOU9RqrBOj" title="Furniture & fixtures useful life">5 years). There were no purchases of property and equipment during the fiscal years ended March 31, 2025, and March 31, 2024. The Company recognized depreciation expense for these assets in the amount of $5,953 and $5,953 during the years ended March 31, 2025 and 2024. SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Office equipment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Leasehold improvement</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zfOc3D8khDy8" style="width: 14%; text-align: right" title="Cost, beginning balance">16,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxjjFM7WELhg" style="width: 14%; text-align: right" title="Cost, beginning balance">12,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20230401__20240331_z4DiJV5kHdVc" style="width: 14%; text-align: right" title="Cost, beginning balance">29,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentAdditions_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNVUuxgGiwxa" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, additions">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentAdditions_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0d4VbRDowUj" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, additions">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentAdditions_c20230401__20240331_zuBAeyxi6d28" style="border-bottom: Black 1pt solid; text-align: right" title="Additions">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zCpsz79F3J7d" style="text-align: right" title="Cost, ending balance">16,839</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zbtrhJB6aL92" style="text-align: right" title="Cost, beginning balance">12,928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20250331_z9Ilp7rEIDKe" style="text-align: right" title="Cost, beginning balance">29,767</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zTZ656TdXX0h" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, additions">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVVCSmPotOx5" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, additions">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20250331_z6cgwytnRgpd" style="border-bottom: Black 1pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-weight: bold">Balance at March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zAsipUk2MaYd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">16,839</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6saEl3Fz2Sk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">12,928</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20250331_zXNtfQ5u4nAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">29,767</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Office equipment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Leasehold improvement</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zqxj3iQgKqb5" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">4,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyRgUMBOlzPf" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">3,587</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20230401__20240331_zDZrPW6bBjD4" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">8,262</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--Depreciation_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zZxbOXgEV2Nc" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">3,367</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--Depreciation_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVP82TXaQyP5" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">2,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Depreciation_c20230401__20240331_zhKkZjHq70ka" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">5,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zkM6w2a9QiPj" style="text-align: right" title="Accumulated depreciation, beginning balance">8,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziNjauCc8sk4" style="text-align: right" title="Accumulated depreciation, beginning balance">6,173</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20250331_zha0yn38mQi2" style="font-weight: bold; text-align: right" title="Accumulated depreciation, beginning balance">14,215</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--Depreciation_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z0vDIkTy8Pm4" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">3,367</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Depreciation_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zFi2r2ZQJwTi" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">2,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--Depreciation_c20240401__20250331_zwbtEGbcG2Ek" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">5,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNCeJkofsBD1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">11,409</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zTxMEeyw8M3k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">8,759</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20250331_zqtVzHjLdZmf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">20,168</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net book value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Balance at March 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zl1dJSlWoHO" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">8,797</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIqY7yaFd5xk" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">6,755</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331_zYQ6xhE7cKI6" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">15,552</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zsBbc11Liauh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">5,430</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zr9W1yu0Ykql" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">4,169</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250331_zSH3L6OIVOye" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">9,599</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> BIOTRICITY INC. Notes to Consolidated Financial Statements Years ended March 31, 2025 and 2024 (Expressed in US Dollars)

12928

P5Y

16839

P5Y

5953

SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Office equipment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold">Leasehold improvement</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zfOc3D8khDy8" style="width: 14%; text-align: right" title="Cost, beginning balance">16,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxjjFM7WELhg" style="width: 14%; text-align: right" title="Cost, beginning balance">12,928</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20230401__20240331_z4DiJV5kHdVc" style="width: 14%; text-align: right" title="Cost, beginning balance">29,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentAdditions_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNVUuxgGiwxa" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, additions">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentAdditions_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0d4VbRDowUj" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, additions">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentAdditions_c20230401__20240331_zuBAeyxi6d28" style="border-bottom: Black 1pt solid; text-align: right" title="Additions">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zCpsz79F3J7d" style="text-align: right" title="Cost, ending balance">16,839</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zbtrhJB6aL92" style="text-align: right" title="Cost, beginning balance">12,928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iS_c20240401__20250331_z9Ilp7rEIDKe" style="text-align: right" title="Cost, beginning balance">29,767</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zTZ656TdXX0h" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, additions">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVVCSmPotOx5" style="border-bottom: Black 1pt solid; text-align: right" title="Leasehold improvement, additions">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentAdditions_c20240401__20250331_z6cgwytnRgpd" style="border-bottom: Black 1pt solid; text-align: right" title="Additions">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-weight: bold">Balance at March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zAsipUk2MaYd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">16,839</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6saEl3Fz2Sk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">12,928</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iE_c20240401__20250331_zXNtfQ5u4nAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cost, ending balance">29,767</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Office equipment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Leasehold improvement</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance at March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zqxj3iQgKqb5" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">4,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zyRgUMBOlzPf" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">3,587</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20230401__20240331_zDZrPW6bBjD4" style="width: 14%; text-align: right" title="Accumulated depreciation, beginning balance">8,262</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--Depreciation_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zZxbOXgEV2Nc" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">3,367</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--Depreciation_c20230401__20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zVP82TXaQyP5" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">2,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Depreciation_c20230401__20240331_zhKkZjHq70ka" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">5,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zkM6w2a9QiPj" style="text-align: right" title="Accumulated depreciation, beginning balance">8,042</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziNjauCc8sk4" style="text-align: right" title="Accumulated depreciation, beginning balance">6,173</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iS_c20240401__20250331_zha0yn38mQi2" style="font-weight: bold; text-align: right" title="Accumulated depreciation, beginning balance">14,215</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--Depreciation_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z0vDIkTy8Pm4" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">3,367</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Depreciation_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zFi2r2ZQJwTi" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">2,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--Depreciation_c20240401__20250331_zwbtEGbcG2Ek" style="border-bottom: Black 1pt solid; text-align: right" title="Office equipment, depreciation">5,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNCeJkofsBD1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">11,409</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zTxMEeyw8M3k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">8,759</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iE_c20240401__20250331_zqtVzHjLdZmf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Accumulated depreciation, ending balance">20,168</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net book value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Balance at March 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zl1dJSlWoHO" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">8,797</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zIqY7yaFd5xk" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">6,755</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20240331_zYQ6xhE7cKI6" style="border-bottom: Black 1pt solid; text-align: right" title="Net book value, beginning balance">15,552</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1pt">Balance at March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zsBbc11Liauh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">5,430</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zr9W1yu0Ykql" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">4,169</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250331_zSH3L6OIVOye" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Net book value, ending balance">9,599</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>

16839

12928

29767

16839

12928

29767

16839

12928

29767

4675

3587

8262

3367

2586

5953

8042

6173

14215

3367

2586

5953

11409

8759

20168

8797

6755

15552

5430

4169

9599

14. SUBSEQUENT EVENTS During the period from April 1 to July 15, 2025, the following events occurred: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company received regulatory approval to operate in Saudi Arabia. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250714__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYeAbdXG93K4" title="Number of shares issued">486,474 additional common shares to Series B preferred shareholders in order to supplement the <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250330__20250330__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zObsnHnr0nX4" title="Conversion of mezzanine equity into common shares">782,913 shares issued prior to March 31, 2025, in relation to its conversion obligations for a conversion of <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvUSPvyIPN0k" title="Number of conversion of shares">25 Series B preferred whose conversion period commenced on March 4, 2025. This conversion of preferred shares is intended to redeem or repay $250,000 in principal and $38,884 in accrued dividends. </td></tr> </table>

486474

782913

250000

38884

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of March 31, 2025 and fair value of common stock adjusted. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of March 31, 2024 and fair value of common stock adjusted for the Reverse Split as of March 31, 2023 of $1.48 and $2.81 per share, respectively.